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ABSTRACT 
PARTICLE SHAPE ENGINEERING FOR IMPROVED DRUG DELIVERY TO 
PERIPHERAL LUNGS BY NON-INVASIVE ROUTE 
Snehal Shukla 
Inhalation of therapeutics has been gaining importance owing to immense 
advantages offered by pulmonary route and have attracted significant advancements in the 
pharmaceutical field. However, pulmonary drug delivery has been challenging because of  
the complexity of the respiratory tract and the existing defense mechanism. The pulmonary 
drug delivery has experienced advances in approaches and strategies to combat the existing 
challenges by tailoring the physicochemical properties of the delivery carriers and enabling 
both localized as well as systemic delivery.  Pulmonary drug delivery is governed by 
several biophysical parameters of the delivery carriers such as particle size, shape, density, 
charge, and surface modifications. Although much attention has been garnered for other 
parameters particle shape effects have been less likely explored. In this exploration we 
studied the impact of particle shape on the aerodynamic properties, ability to escape 
macrophage uptake and therapeutic effectiveness of particles against lung cancer. 
Interestingly, the results of in-vitro lung deposition demonstrated improved aerodynamic 
properties of the rod-shaped with high aspect ratio as compared to spherical particles. 
Results of macrophage uptake demonstrate that high aspect ratio particles were internalized 
less when compared to spherical particles. On the contrary, results of cellular uptake by 
small cell lung cancer cells revealed preferential uptake of rod-shaped particles than 
spherical particles. The results were further validated by in-vitro tumor simulation studies 
wherein rod-shaped particles displayed enhanced anti-tumorigenic activity against spheres. 
Moreover, the high aspect ratio particles also demonstrated diminished cardiotoxicity 
activity; adverse effect of DOX limiting its therapeutic use. These results provide valuable 
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Respiratory diseases are defined as pathological condition which affect the 
respiratory airways and other structure of lungs impacting their function [1]. They can be 
classified based on the severity of disease as; 1) mild and self-limiting: common cold and 
2) chronic and life-threatening: asthma, chronic obstructive pulmonary disease (COPD), 
lung cancer etc. As per WHO (World Health Organization) report, respiratory diseases 
account for ~30% deaths occurring worldwide [2]. The global burden of mortality due to 
respiratory diseases has been contributed significantly by lower respiratory infections, lung 
cancer and COPD accounting ~16.2 million deaths [2]. Pulmonary drug delivery has been 
serving as first-line treatment for several respiratory diseases since the 20th century. 
Characterized by large surface area (~100 m2 in adult humans), extensive blood capillary 
network, very thin absorptive mucosal membrane and air-blood interface facilitating 
increased permeation, enhanced absorption and improved pharmacokinetics of inhaled 
therapeutics, pulmonary delivery offers diverse advantages [3,4]. Significance of 
pulmonary delivery also involves features such as overcoming first pass metabolism, 
limited degradation of therapeutics , reduced side effects, increased localized concentration 
and enhanced therapeutic effect with only a fraction of dose [5,6]. For example, salbutamol 
when given orally requires an oral dose of 2 mg to 4 mg while only 0.1mg-0.2 mg dose is 
required upon inhalation to provide the same therapeutic effect [7]. Similarly, in a 
comparative clinical study performed in healthy men, difference in pharmacokinetics of 
oral vs. inhaled terbutaline was observed wherein inhalation of drug resulted into ~3 folds 
increase in bioavailability of the drug as compared to oral administration [8].  
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Local delivery to lungs have been widely explored for treatment of pulmonary 
diseases and advances has been made over decades to develop efficient lung delivery 
systems. Development of modern inhalation devices such as nebulizers, dry powder 
inhalers and metered dose inhalers have improved the delivery of therapeutics to lungs. 
Commercially available inhalation products for such as Advair® (Fluticasone and 
Salmeterol), Symbicort® (Budesonide and Formoterol), Triohale® (Ciclesonide, 
Formoterol and Tiotropium), TOBI® (Tobramycin), Colobreathe® (Colistimethate) have 
perceived the success of pulmonary drug delivery for treatment of asthma, COPD, and 
bacterial infections [9]. Recent FDA approval of Arikayce® inhalation suspension 
comprising of amikacin encapsulated liposomes have paved the path for amalgamation of 
nanotechnology with traditional pulmonary delivery methods [10]. Despite these 
advancements, pulmonary delivery systems suffers several limitations such as short half-
life, rapid elimination and low dose deposition impacting bioavailability followed by 
frequent dose administration thereby passively impacting patient compliance [11,12]. To 
address these issues, it is essential to understand the anatomical challenges existing and 
tailor the biophysical parameters accordingly to design inhalable carriers which could lead 
to development of optimized efficient carrier systems. 
1.2 Physiological structure of the respiratory tract- A brief overview 
The anatomical structure of human respiratory tract influences the flow passage of 
air subsequently impacting the orientation and deposition of inhaled particles. The 
respiratory tract is divided into two parts: 1) the upper respiratory tract consisting of nose, 
nasal cavity and pharynx which is responsible for transporting air from external 
environment to  the sites of gas exchange and 2) the lower respiratory tract comprising of  
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larynx, tracheobronchial region and alveolar region which are involved in gas exchange 
[13]. Pulmonary airway structure originates from the oro-pharynx region followed by 
larynx and trachea. The trachea is fused with the larynx and enters in each side of lungs as 
primary bronchi which divides into bronchioles paving the pathway for the air to reach the 
respirable region in lungs [14]. The bronchioles branch into primary bronchioles, 
secondary bronchioles, and respiratory bronchioles. Respiratory bronchioles terminate into 
alveolar region comprising of alveolar ducts and alveolar sac [15]. The bronchi and 
bronchioles are responsible for conducting the air to the alveolar region where the gas 
exchange takes place. About 480 million alveoli are present in an adult lung and each 
alveolus is lined with extensive pulmonary capillary resulting into huge surface area of 70-
140 m2 being available at the air-blood barrier for the exchange to take place [16,17]. 
In terms of cellular composition, respiratory tract is formed by continuous layer of 
epithelial cells which are designed to perform specific functions such as: providing barrier 
for protection against harmful agents, muco-ciliary clearance, secrete protective substances 
to destroy the external agents and modulate immunogenic responses [18]. The epithelium 
layer of the respiratory tract is shown to be possess about 40 different cells for 
accomplishing successful respiration, indicating the complexity and heterogeneity as it 
progresses from the trachea to the alveolar region as seen in Figure 1 [14,19]. The airway 
epithelium in the conducting airways (trachea and bronchi) is pseudostratified and 
columnar comprising of goblet cells (secreting mucus), basal cells and ciliated cells 
(causing muco-ciliary escalation). The apical membrane of the cells have tight junctions 
thereby providing a tight physical barrier for the entry of pathogen [20]. The conducting 
airways epithelial region is also covered with pulmonary mucous lining. This mucus barrier 
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is composed of two different layers: the top layer is viscous gel like comprising of several 
macromolecules having capacity to entrap wide range of inhaled particulates and is 
continuously cleared by ciliary beating [21]. Mucus is comprised of water (95–97%), 
mucin (glycoprotein), immunoglobulins, albumin, lysozyme, and lactoferrin [22]. While 
the bottom layer is the periciliary layer which is a thin watery-sol layer composed of 
minimal glycoproteins and proteins. The periciliary layer prevents mucus penetration in 
the periciliary space and help in facilitating the ciliary activity [23]. In adults, the mucus 
layer is reported to be renewed every 20 minutes and the mucus clearance rate is recorded 
to be 3–25 mm/min [24]. Farther down the respiratory airways in the bronchiole region, 
epithelial layer consist of simple columnar cells having shorter cilia which are more like 
cuboidal shape and secretory club cells also known as Clara cells (Figure. 1) [14,20]. 
Moreover, the thickness of mucus lining which is ~ 10–30 μm in the tracheal region also 
decrease progressively in the distal bronchioles to 2–5 μm [24].  
The alveolar region has very a thin epithelial layer which is comprised of two types 
of pneumonocytes: alveolar type I (AT-I)  and alveolar type II (AT-II) cells. AT-I cells are 
large, flat squamous cells covering ~90% of the alveolar surface and are responsible for 
gas exchange due to their thin gas permeable membrane [20,25]. AT-II cells are small 
cuboidal cells responsible for secretion of surfactants which lines the alveolar epithelium 
providing the air-liquid interface [26]. The presence of surfactants help in reducing the 
surface tension and thereby prevent the collapse of alveolar surface [27]. Pulmonary 
surfactant comprises of a complex mixture of 92% lipids and 8% surfactant proteins (SP) 
[28]. Amongst, the surfactant proteins SP-A and SP-D are large hydrophilic SPs also 
known to induce immunomodulatory response by binding to the invading pathogen, 
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causing opsonization and further inducing phagocytosis [28,29]. While SP-B and SP-C are 
the hydrophobic SPs responsible for maintaining the surfactant adsorption dynamics [30].  
Resident alveolar macrophages present in the interstitial space are responsible for engulfing 
any pathogen or debris of inhaled particulate [31]. 
 
Figure 1: Schematic representation of cells present in different regions of the respiratory 
structure [14]. 
1.3  Understanding the Fate of particles upon entry into the respiratory tract 
As can be seen in Figure 2  after inhalation, the particles first enters the central 
lungs wherein they interact with the mucociliary layer. Depending on the physicochemical 
properties the particles may either permeate the layer and reach the epithelia or may get 
cleared from lungs via mucociliary clearance [32]. If the particles do not deposit and 
successfully evade clearance in the central lung, they reach the peripheral lung (Figure 2). 
The biophysical parameters of the particles may then determine the deposition of particles 
in the conducting airways and its successful absorption [17]. The inhaled particles may get 
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internalized by alveolar macrophages depending on the particle properties which will be 
discussed in detail in the following sections. 
 
Figure 2: Fate of particles upon entering lung. The figure represents following steps 1) 
deposition of particles on the airway epithelia 2) absorption/translocation of particle from 
epithelia to blood circulation and 3) clearance by existing pulmonary barriers [26].  
1.3.1 Step 1: Deposition of particles in respiratory tract  
Upon entering the respiratory tract, inhaled particles are carried further in the 
respiratory airways by the tidal air and mechanical forces such as gravity, inertia and 
impulse collision along with the gas molecules resulting into deviation of their trajectories 
from the streamlines causing them to deposit at varied site [33].  Inhaled particles in lungs 
tend to deposit in the lungs based on following deposition mechanisms governed by their 
physicochemical properties: 
Inertial impaction: Larger particle (>5 µm) tend to deposit via inertial impaction wherein 
the particles are incapable of streamlining themselves and deviate from the flow each time 
when there is a bifurcation or change in the flow direction [34]. This deposition pattern is 
observed in upper airways where the particles deviating from their trajectories impact the 
site of deposition due to sudden change in the direction of air flow [35].  
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Gravitational sedimentation: Gravitational sedimentation refers to settling of particles 
under the influence of gravity and is observed by particle within 1 to 8 µm range [33]. This 
deposition mechanism has direct relationship with the particle size and residence time of 
particles in the airways [35]. Gravitational sedimentation is commonly observed in smaller 
airways and alveolar region where the residence time is high and the particles have less 
distance to cover before reaching the airway walls [36]. 
Diffusion (Brownian motion): Diffusion is observed by particles of <0.5 µm which are 
deposited into alveolar region by this deposition patter due to low air velocity in the region 
[37]. Brownian motion of the particles occur upon collision with gas molecules resulting 
into random motion of the particles [36]. This pattern of deposition has inverse relationship 
with particle size where smaller the particle, higher is this deposition pattern observed 
[35,38].  
Interception: This deposition mechanism is observed for particle that are fiber-like, 
elongated and have high length to width ratio (also known as aspect ratio). An increase in 
elongation of particle results into increase in probability of deposition  by this mechanism 
[33,36,38] 
Inhaled particles are deposited in different regions of the lung based on their size, shape, 
density, charge, and surface properties of the particles. After deposition, the aerosol 
particulates must overcome the existing pulmonary barriers to reach their targeted site. The 
respiratory system eliminates the inhaled particles using pulmonary barriers depending on 
the site of deposition (Figure. 2). 
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1.3.2 Step 2: Drug dissolution and absorption in the lungs- Translocation of 
particles 
After deposition of particle on the respiratory surface, the particle must dissolve or 
permeate the epithelia (bronchial or alveolar) for absorption [32]. Hydrophilic molecules 
are rapidly absorbed and translocated to the systemic circulation; however, large 
hydrophilic protein molecules post-deposition can interact with pulmonary surfactants 
resulting into aggregation of particles hindering their absorption and eventually being 
phagocytosed by alveolar macrophages [12]. On the contrary studies have reported that 
lipophilic particles after deposition encounters with pulmonary surfactant which enhances 
their permeability, solubility, and bioavailability [39,40]. Similarly, particles surface 
modification also determines the translocation ability of the deposited particles. Cationic 
and hydrophilic surfaces are reported to exhibit prolonged absorption and minimal 
translocation when compared to neutral or negatively charged particles [41]. Choi et al., 
have evaluated the translocation of florescent labeled nanoparticles of varied size ranging 
from 5 to 300 nm and functionalization after intratracheal administration in Sprague-
Dawley (SD) male rats. Results illustrated that nanoparticles of < 36nm particle size 
translocated from lung to lymph nodes, while extremely (<6 nm) small nanoparticles 
rapidly translocated to lymph nodes and systemic circulation following which they were 
cleared by kidneys. They have also demonstrated the impact of surface charge on 
translocation of particle, wherein cationic charged particles inhibited pulmonary 
translocation while neutral (polyethylene glycol coating) or zwitterionic (cysteine coating) 
resulted into prompt translocation to various target organs [42].  Liu et al, assessed the in-
vivo impact of size of radiolabeled particles (20 nm to 5 µm) on translocation from lungs. 
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Large sized particles (~2 to 5 µm) were cleared by mucociliary clearance and translocated 
to systemic circulation and other organs such as kidney, liver, spleen, thyroid, and heart. 
On the other hand, smaller particles were found to have prolonged retention in lung and 
translocated to blood, liver, and thyroid with reduced clearance [43]. Recently Buckley et 
al., performed inhalation study on rats to evaluate the effect of particle size on clearance 
and translocation of radioactive labeled iridium loaded nanoparticles ranging from 10 to 
75 nm in size. They have reported low levels of particle size dependent translocation of 
nanoparticles from lungs to organs such as kidney, liver, and brain with maximal deposition 
occurring in kidney which subsequently is cleared [44]. Therefore, the physicochemical 
properties of the inhaled particles governs the translocation of particles to the systemic 
circulation, lymphatic system and or other target organs. 
1.3.3 Step 3: Overcoming pulmonary barriers impacting the deposition of aerosol in 
lungs. 
A) Mucociliary clearance 
Mucociliary clearance is the first line of defense mechanism offered in the conducting 
airways. The principal of mucociliary clearance involves entrapment of inhaled particulates 
in the thick mucus layer and escalating it by the ciliary beating towards larynx or pharynx 
where they are either swallowed or coughed [45]. After deposition of particles in the 
tracheobronchial region, the particles encounter with thin luminal surfactant lining 
resulting into displacement of particle from the air interface to the underneath mucus layer 
[46]. As the mucus layer is continuously moving proximally, the entrapped particles are 
cleared immediately by either coughing or swallowing [3]. If the particles successfully 
escape the mucociliary escalation, pulmonary dissolution of drug in the epithelial lining is 
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required for effective absorption of the inhaled drug. Hydrophilic drug molecules which 
are freely soluble are rapidly absorbed while hydrophobic molecules are retained longer 
and is highly susceptible to respiratory clearance [5].  Mucociliary clearance rate is known 
to be increased with the increase in thickness of the mucus layer and the diameter of the 
airways . Therefore, particles depositing in the proximal conducting airways are escalated 
faster towards the larynx/pharynx resulting into their clearance [5]. Stahlhofen et al., has 
demonstrated that particles larger than 6µm are easily entrapped in the mucus layer and are 
subjected to mucociliary clearance while smaller particle are retained comparatively for 
longer time [47,48]. However, Smith et al, demonstrated that particle size difference does 
not impact the airway clearance of gold particles (dp 1.2 µm) and polystyrene (dp 5 µm) 
administered using bonus inhalation and that both the particles displayed similar retention 
in the lungs [49]. Furthermore, studies performed by Henning et al.  revealed no significant 
difference in the mucociliary clearance of particles evaluated for size ranging from 50 nm 
to 6000 nm. On the contrary, material properties and surface chemistry of the particles were 
found to impact the mucociliary clearance [50]. Mucociliary clearance serves as an 
important defense mechanism against the invading agents, however, in some disease 
conditions its function is impaired which affects the retention and efficacy of the inhaled 
drugs [51]. Therefore, designing delivery carriers to impart prolonged residence and 




B) Clearance by Alveolar Macrophages  
Alveolar macrophages are present in the interstitial space in the alveolar region and are 
recognized as the first line of cellular host defense [52]. Macrophages are phagocytic cells 
which secret various cytokines or chemokines to activate the immune system against the 
invading pathogen or particulate matter [53]. Alveolar macrophages display non-
absorptive clearance mechanism. These macrophages adhere to the inhaled particle by 
either receptor binding or electrostatic interaction and engulf them. The engulfment can be 
mediated by surface cavitation, vacuole formation or pseudopod formation [54].  
 
Figure 3: Schematic representing the process of phagocytosis of particles by macrophages 
[55].   
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 Figure 3 represents detailed phagocytosis process of macrophage. As can be 
seen the first step of phagocytosis involves particles being present in the vicinity of 
macrophages followed by attachment of the particle to the surface of macrophages. Upon 
attachment of particle, pseudopod (cup-like structure) formation occurs via actin 
remodeling for engulfment of the particles. After successful engulfment of particle, 
phagosome formation occurs which later fuses with lysosome to form phagolysosome 
(Figure 3). The phagolysosome degrades the particles by enzymatic action or acidic 
environment and discharge the waste in the lymphatic system [55].  
C) Clearance by Enzyme Degradation 
Inhaled particles are also susceptible to degradation in lungs due to the presence of several 
enzyme. Several enzymes are present in lung to maintain its physiological function and 
serve as defense mechanism against the inhaled particles and xenobiotics along with 
preserving the homeostasis [56]. Although, lung has relatively low level of enzyme activity 
compared to liver, it is more comparatively more inducible [57]. Predominantly enzymes 
belonging to cytochrome (CYP) P450 family such as flavin-containing monooxygenases 
(FMO), monoamine oxidase (MAO), aldehyde dehyrogenase, NADPH-CYP450 reductase 
is found throughout lungs [39]. Carboxylesterases responsible for hydrolysis of diverse 
functional groups such as esters, amides, thiols and fatty acids are found to expressed in 
human lungs [58]. Esterase, liable for cleavage of ester bonds are found extensively in 
alveolar macrophage and in minimal amount in alveolar type I and II cells [4]. Proteases 
responsible for degradation of proteins and peptides are present on the surface of bronchial 
and alveolar epithelial cells [59].   
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1.4 Essentials for Successful Pulmonary Delivery 
For efficient delivery to lungs, inhaled delivery carriers must reach the desired site of action 
which in most respiratory disease is peripheral lungs, and evade phagocytic uptake by 
alveolar macrophages [1,19]. Advances in the field of pulmonary drug delivery have 
identified several tunable bio-physical parameters that influences the drug delivery to the 
lungs. Parameters such as particle size[4–6], density[7–9], rigidity[10,11], 
hygroscopicity[12–14] and surface chemistry[15–17] have been reported to govern the fate 
and deposition of particles in lungs. 
Despite the advancements, dug delivery to lungs suffers limitations such as low dose 
deposition, rapid elimination of inhaled particles by existing defense mechanisms, short 
half-life, impacting bioavailability and patient compliance [7,18]. The importance of 
particle shape was illuminated after understanding the enhanced and prolonged retention 
of respiratory disease-causing microorganisms such as Mycobacterium tuberculosis, 
Hemophilus influenza, Legionella pneumophila and Pseudomonas aeruginosa in lungs 
[20–22]. While inhaled particulate delivery carriers are known to be rapidly eliminated 
from lungs, these microorganisms on the other hand demonstrate prolonged retention in 
the peripheral lungs after overcoming the existing lung defense mechanisms, thus causing 
severe to cause various respiratory diseases. It is interesting to comprehend that the shape 
of these micro-organisms causing respiratory diseases in peripheral lung are known to be 
aspherical or rod rod-like, shapes which is suggestive to play an important role in 
enhancing their aerodynamic properties[23], and evading clearance by lungs’ defense 
mechanisms   [23,24].  
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In addition to aspherical Additionally, microorganisms, rod-shaped, or fibrous particles 
such as asbestos and carbon nanotubes are deposited in the alveolar region and result into 
adverse health effects implying that particle shape enhances aerodynamic behavior of 
particles [25,26].   Several computational fluid dynamic (CFD) studies have revealed the 
deposition performance of  fibers or elongated particles in lungs wherein they are reported 
to orient themselves parallel to airflow and hence travel preferentially to the distal region 
of lungs [27–29].   However, experimental respiratory deposition data or in-vitro deposition 
behavior of such anisometric rod-shaped or fibrous particles has not been thoroughly 
examined [30], . Thereby indicating the dire need to experimentally investigate the role of 
particle shape further experimentally on aerodynamic behavior and peripheral lung 
deposition of aspherical particles in lungs.  
Along with particle deposition, cellular internalization is another paramount factor 
deciding the therapeutic fate of particles in lungs. Several studies have highlighted the 
details of particle shape and its role in phagocytic uptake wherein rod-shape or filamentous 
particle being successful in evading the uptake by macrophage [31–33]. It has been shown 
that not only the shape of particle but also the orientation of particle or target geometry 
encountering the surface of cells determines their internalization of into target cells [31,34]. 
Target geometry of particles is defined by the contact angle wherein particles with high 
curvature regions are known to escape the uptake by macrophages [32,34]. On the other 
hand, studies have reported that non-spherical particles are readily internalized by various 
cancer cells as compared to their counterparts [33,35,36]. In a recent study,  by He and 
Park, examined the influence of 20 different shapes and sized particles on the 
internalization by cancer cells. Their results have reported that local interaction between 
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particle and cell surface determined the internalization fate of particles, and elongated 
particles with sharper angular features were readily internalized [36]. Thus, fine fine-tuning 
the particle shape of inhaled delivery carriers may serve as a potential strategy to address 
the existing limitations of pulmonary drug delivery systems and improving their 
therapeutic efficiency.   
The aim of the present study is to explore novel strategy of particle shape fabrication 
modulation for development of effective inhaled delivery carriers possessing peripheral 
lung deposition with efficient aerodynamic properties and capability to evading 
macrophagic uptake. We have utilized Doxorubicin hydrochloride (DOX) as a model drug 
to evaluate the influence of particle shape on the therapeutic effectiveness of the delivery 
carriers. The aerodynamic properties of the varied size and shaped particles was evaluated 
using in-vitro lung deposition simulator, next generator impactor (NGI). Further, 
therapeutic activity of various DOX-conjugated particles was assessed by systematic in-
vitro studies performed on small cell lung cancer chosen as a model pulmonary disease. 
Additionally, as DOX is known to be limited for its therapeutic use because of 








“Particle shape modification enables significant deep lung deposition with efficient 
aerodynamic properties”. 
To test this hypothesis, the following questions will be addressed in this exploration: 
1.) Could the particles with varied shape be fabricated? 
2.) Does particle shape influence the aerodynamic behavior? 
3.) Does particle shape impact the uptake by macrophages? 
4.) Could particle shape improve the efficacy of drug against lung cancer? 








3.0 Materials and Methods 
3.1 Materials 
Polystyrene microspheres of different sizes (0.5 µm, , 6.0 µm and 10µm) were 
purchased from PolySciences, Inc. (Warrington, PA, USA). Poly (vinyl alcohol) (PVA-
fully hydrolyzed) was obtained from Sigma Aldrich (St. Louis, MO, USA). Doxorubicin 
hydrochloride (DOX) was procured from LC laboratories (Woburn, MA, USA). Phosphate 
Buffer saline (PBS) pH 7.5, dimethyl sulfoxide (DMSO) and HPLC grade solvents such as 
acetonitrile and water were purchased from Fisher Scientific (Hampton, NH, USA). 
Various other assay kits and other molecular biology grade reagents were obtained from 
several sources which have been listed along with their respective methods. 
3.2 Cell Culture 
Murine macrophages RAW 264.7 cells, multidrug resistant human small cell lung 
cancer (SCLC) cell line H69AR and rat cardiomyoblasts H9c2 cells were acquired from 
American Type Culture Collection (ATCC) (Manassas, VA, USA). H69AR cells were 
cultured in Roswell Park Memorial Institute (RPMI) 1640, while RAW 264.7 and H9c2 
cells were grown in Dulbecco’s Modified Eagle’s Medium (DMEM) (Corning Inc., 
Corning, NY, USA), supplemented with 10% fetal bovine serum (Atlanta Biologicals, 
Flowery Branch, GA, USA), 1% sodium pyruvate and 1% penicillin-streptomycin 
(Corning Inc., Corning, NY, USA) by incubation at 37°C under 5% CO2. 3-(4,5-
dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) and crystal violet were 
obtained from Fisher Scientific (Hampton, NH, USA). Vectashield hardset mounting 




3.3 Particle Fabrication 
Spherical particles were fabricated to rod-shaped particles using one dimension 
stretching method as reported earlier with slight modifications [9]. As can be seen in 
Figure 1A, carboxylated functionalized polystyrene particles of different sizes (0.5 µm, 
6.0 µm and 10µm) were dispersed in poly-vinyl alcohol (PVA) film; and were subsequently 
stretched to desired length in an oil bath using custom made apparatus. 
3.3.1 Film preparation 
Briefly, 5% PVA (~2 g in 30 ml of water) was dissolved in water at 85°C with 
continuous stirring. After complete dissolution of PVA, 2% (w/v) glycerol was added as 
plasticizer to the PVA solution. The resultant mixture was then allowed to cool and 
spherical polystyrene particles (~0.75 mL) were added to this mixture. The mixture was 
later carefully poured on a 13 × 13-cm petri plate to avoid entrapment of any air bubble in 
the film. Resultant films were dried completely for ~48 hrs, and stored in a dry place until 
further use. 
3.3.2 Film stretching 
The dried film was cut into sections of ~5 × 5 cm and mounted on the custom-made 
stretchers [60,61]. The stretcher comprised of two aluminum blocks mounted on a screw. 
After mounting the film on the blocks, the length of the film in between the two blocks was 
measured which helped in determining the final distance for separation. The stretcher along 
with the mounted film was immersed in hot mineral oil (~120°C) for 5 min and stretching 
was performed by keeping the stretcher in the oil bath (Figure 4). Stretching of the film 
was performed to 3 folds or 6 folds of the initial length of film mounted between aluminum 
blocks to obtain rod shaped particles of varied lengths. Short rods (SR) were obtained upon 
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stretching the films to 3 folds of its initial length while 6 folds stretching resulted into long 
rods (LR) After stretching to the desired distance, film was cooled for 10 minutes before 
unmounting from the stretcher. 
3.3.3 Particle recovery 
The stretched film was removed from the stretcher and cut into extremely small 
pieces which were dissolved in water at 70°C. The particles were washed by centrifugation  
at 10,000xg for 10 minutes with water. The washing was performed thrice to remove PVA 
from the mixture. The recovered stretched particles were finally redispersed in 1 mL of 
water and stored at 4°C until further use.  
 
Figure 4: Schematic representation of fabrication of particles of varied shapes using the 
stretching method.  
3.4 Structural Morphology 
Morphology of the fabricated particles were examined using Nova Nano SEM™ 
450 and Helios Nano Lab 660 (FEI, Hillsboro, Oregon, USA). Briefly, the particles were 
dried on the SEM pin stub (Ted Pella, Inc., Redding, CA, USA) and then sputter coated 
with palladium for 90s and imaged at 5 kV. The dimensions of particles were obtained by 




3.5 Conjugation DOX on Spherical and Stretched Particles 
Conventional carbodiimide chemistry was used for conjugating carboxylate groups 
on particles’ surface to the amine group of DOX resulting into formation of amide bond as 
shown in Figure 5. Briefly, 1mg of particles were added to aqueous solution containing 
excess 1-Ethyl-3-(3-dimethylaminopropyl) carbodiimide (EDC) and N-hydroxy 
succinimide (NHS) and stirred for 3 hrs. at room temperature. This reaction allowed the 
carboxylic groups to be activated. Particles were then centrifuged to remove the excess of 
EDC and NHS followed by washing to ensure complete removal of the reagents. The 
activated particles were then incubated with excess amount of DOX (1 mg) for 72 hrs. 
Following incubation period, the unconjugated drug was separated by centrifugation at 
10,000xg for 10 minutes and further washing particles twice with water. Additionally, the 
conjugated particles were finally washed with methanol to remove any free DOX. The 
DOX-conjugated particles were finally resuspended in water and stored at 4°C for further 
analysis. Spheres of all size used for conjugation were also recovered from the film after 
placing them in the hot oil bath as mentioned in section 3.3. This was done to expose the 
carboxylic groups of spheres to the conditions like that of SR and LR. 
The amount of drug conjugated was determined by measuring the absorbance at 




Figure 5: Reaction scheme for conjugation of DOX to the carboxylic groups present on 
the surface of the polystyrene particles using EDC-NHS chemistry. 
3.6 Characterization of DOX Conjugation 
3.6.1 DSC studies 
Calorimetric studies of DOX, blank 10µm particles, physical mixture of DOX and 
blank particles and DOX-conjugated particles were performed using DSC 6000 (Perkin-
Elmer; Waltham, MA, USA) equipped with an intra-cooler accessory. About 1.5 mg of 
sample was sealed in an aluminum pan, while a sealed empty pan was maintained as 
reference. The samples were analyzed over the temperature range of 50°C to 300°C at a 




FT-IR analysis of the samples were performed using a Spectrum-100 (Perkin-
Elmer, Inc.; Shelton, CT, USA) equipped with attenuated transmittance reflectance (ATR). 
The spectra of DOX, blank particles, DOX-conjugated particles, and physical mixture of 
DOX and blank particles were measured for comparison over 1000-4000 cm-1 range. 
3.7 In-vitro Pulmonary Deposition Behavior 
In-vitro deposition behavior reflects the aerodynamic behavior of the inhaled 
particles and can be used to estimate the deposition pattern of particles in-vivo [62]. In-
vitro deposition behavior of DOX-conjugated particles were assessed using Next 
Generation Impactor (NGI, MSP corporation, MN, USA) to predict the impact of particle 
shape on aerodynamic properties using previously reported method [63,64].  Briefly, 2 mL 
of DOX-conjugated particles at concentration of 450 µg/mL were nebulized using jet 
nebulizer, PARI LC PLUS® nebulizer cup connected with Pari FAST-NEB compressor 
system into pre-cooled impactor under vacuum maintained at 15 liters/minute for 4 
minutes. The NGI was previously cooled at 4°C for 90 minutes to avoid heat-transfer which 
otherwise may cause shrinkage of the nebulized droplets, thus causing impact on particles’ 
deposition behavior [65]. Following nebulization, particles deposited on each stage of NGI 
were collected using a cell scrapper and were analyzed for drug amount present using 
TECAN plate reader (Tecan Group Ltd., Männedorf, Switzerland), as described earlier. 
Aerodynamic parameters such as fine particle fraction (% FPF) and mass median 
aerodynamic diameter (MMAD) were calculated from the amount of drug deposited in 
each stage. % FPF was determined as  the fraction of emitted dose deposited in the NGI 
23 
 
stages with <5.39 μm while MMAD (dae<5.39 μm) representing the aerodynamic particle 
size distribution was calculated using log-probability analysis (n=3) [64]. 
All the further experiments were performed using10µm DOX-conjugated particles 
(spheres, short rods, long rods). 
3.8 In-vitro Release Studies 
In-vitro release studies of all 10µm DOX-conjugated particles (spheres, short rods, 
long rods) were performed using release method as previously reported with slight 
modifications [66]. Briefly, 2 mg of DOX-conjugated particles were dispersed in 5 mL of 
PBS pH 7.4 and acetate buffer pH 5.5. The samples were incubated at 37°C with 
continuous shaking at 50 rpm. At predetermined intervals, the samples were centrifuged at 
10,000×g for 10 minutes, and obtained supernatants were analyzed at 485 nm wavelength 
using TECAN plate reader to determine the amount of DOX released. 
3.9 Stability Studies 
Stability studies of 10µm DOX-conjugated particles were performed by storing the 
samples at two different conditions: 4°C (representing normal refrigerated storage) and 
40°C/75%RH (accelerated stability storage) for a time interval of 15 days. Following the 
storage period, the samples were analyzed in terms of particle size along with aspect ratio, 
change in particle shape and amount of DOX-conjugated as µg of DOX/mg of particles. 
3.10 Cellular Uptake Studies 
The uptake of different shaped DOX-conjugated particles and free DOX was 
evaluated on RAW 264.7 murine macrophages and H69AR human SCLC cells using 
previously reported method [67]. Briefly, 1.0×104 cells/chamber were seeded on 8-
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chambered imaging coverslip (Eppendorf, Hauppauge, NY, USA) and were incubated 
overnight at 37°C and 5% CO2. Cells were treated with DOX-conjugated particles or free 
DOX (2.9 µg/mL) for 3 hours, following which they were washed twice with ice-cold PBS 
(1X). The cells were then fixed using 4% paraformaldehyde for 10 mins and then again 
washed with PBS (1X) to remove excess paraformaldehyde. The coverslip was separated 
from chamber and was mounted on a clear glass microscopic slide using VECTASHEILD 
hardset mountant containing DAPI (H1500, Vector laboratories). The cells were then 
imaged using EVOS-FL fluorescence microscope (Thermo Fisher Scientific, Waltham, 
MA, USA) at 20X magnification. 
In addition to qualitative assessment, intracellular quantification of DOX was also 
performed for understanding cellular uptake according to previously published method 
[67]. Briefly, RAW 264.7 macrophages and H69AR cells were seeded at a density of 1.0 
x 106 cells/well in 6-well plates and incubated overnight at 37°C and 5% CO2. The cells 
were then treated with DOX and DOX-conjugated 10µm particles for 1 hr. and 3 hrs. After 
the respective time interval, the treatment was aspirated, and cells were washed twice with 
ice-cold PBS (1X). The cells were scrapped using cell scrapper and centrifuged to obtain a 
cell pellet. The obtained pellet was washed twice using 1X PBS and was lysed using 100 
µL DMSO. The lysed pellet was centrifuged again, and the obtained supernatant was 
subjected to fluorometric analysis. The florescence intensity of DOX in each treatment 
group was determined at excitation wavelength of 480 nm and emission wavelength of 590 
nm using TECAN plate reader (Tecan Group Ltd., Männedorf, Switzerland) [68]. 
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3.11 Cytotoxicity Assessment 
The cytotoxicity studies of free DOX and DOX-conjugated 10µm particles were 
performed on RAW 264.7 macrophages, H69AR DOX- resistant SCLC cells and H9c2 rat 
cardiomyoblasts using MTT assay. Briefly, RAW 264.7 and H69AR cells were seeded at 
a density of  2.5×103 cells/well  while H9c2 cells were seeded at 1.5×103 cells/well in tissue 
culture treated 96 well plates (Eppendorf, Hauppauge, NY, USA), and were incubated 
overnight at 37°C/5% CO2. Next morning, cells were treated with different DOX-
conjugated particles or free DOX; and were incubated for specific time points; RAW 264.7 
macrophages (24 hrs. and 48 hrs.), H69AR cells (72 hrs.) and H9c2 cells (24 hrs.). After 
respective treatment period, media was removed and MTT (1 mg/mL) was added followed 
by 2 hrs. of incubation. Later, DMSO was added to each well after aspirating MTT solution. 
Addition of DMSO helps to dissolve the formazan crystals formed during incubation of 
cells with MTT solution. The plates were then shaken for 30 minutes on plate shaker and 
the optical absorption was measured at 570 nm using TECAN plate reader (Tecan Group 
Ltd., Männedorf, Switzerland). Cytotoxicity of particles was determined by comparing the 
cell viability against the non-treated cells used as control groups. IC50 values were 
determined by normalizing and transforming the data to log value using Graph Pad Prism 
Software Version 6.0. 
3.12 In-vitro Tumor Simulation Studies 
In-vitro tumor simulation studies were performed to understand the therapeutic effect 
of DOX and DOX-conjugated particles by mimicking the in-vivo tumorigenic conditions. 
Briefly, H69AR small cell lung cancer (SCLC) cells were seeded at a density of 1.0×103 
cells/well in a 96-well U bottom ultra-low attachment spheroid plate (Nuclon® Sphera, 
26 
 
Thermo Fisher Scientific, Waltham, MA, USA) and incubated for 3 days at 37°C/5% CO2. 
After incubation, cells were treatment in two different regimens: 1) single dose wherein 
treatment was provided once only i.e., at the start of experiment and 2) multiple doses 
where treatment provided every three days until the end of experiment (6 days). During the 
treatment, half of the initial volume of media was replenished to avoid the possibility of 
tumor aspiration or tumor damage. The tumors were characterized using several means as 
outlined below to evaluate the anti-tumor activity of treatments.  
a. Optical Imaging – Tumor spheroids were imaged at pre-determined intervals using 
LMI-6000 inverted microscope (LAXCO, Bothell, WA, USA). The morphometric 
parameters such as spheroid diameter and spheroid volume were calculated from the 
images using Image J analysis software. 
b. Cell Viability Assay – % Cell viability of tumor spheroids was determined using Cell 
Titer-Glo™ 3D assay kit (Promega, Madison, WI, USA). Briefly, at the end of 
experiment (Day 6), 50 µL of Cell Titer-Glo® 3D reagent was added in each well after 
removing 150 µL of media (n=3 for each treatment group). After incubation of 30 
minutes, the luminescence signal was measured using TECAN plate reader (Tecan 
Group Ltd., Männedorf, Switzerland). The % cell viability was calculated for each 
treatment group by comparing the viability against control. 
c. Viable Cell Imaging – Viable cell imaging of the tumor spheroids was performed on 
day 6 using calcein AM dye (Biotium, Fremont, CA, USA) which stains the viable cells 
with green florescence. Briefly, 100 µL of florescent dye was added to each well after 
carefully aspirating the treatment, followed by 30 minutes of incubation in dark. 
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Labeled spheroid cells were imaged using EVOS FL florescence microscope (Thermo 
Fisher Scientific, Waltham, MA, USA) at 4X magnification. 
3.13 Evaluating Impact on Cardiotoxicity of DOX 
3.13.1 Lactate Dehydrogenase (LDH) Assay  
Cardioprotective effect of DOX-conjugated particles as against free DOX was 
evaluated in H9c2 rat cardiomyoblasts using LDH assay. LDH-Glo™ cytotoxicity assay 
(Promega, Wisconsin, MI, USA) kit was used  to evaluate the toxicity of free DOX and 
DOX-conjugated particles by measuring the LDH released from the cytosol due to loss of 
membrane integrity of the cells. Briefly, H9C2 cells were plated in 24 well tissue culture 
plates at 8.0×104 cells/well density and were incubated overnight at 37°C/5%CO2. 
Following incubation, the cells were treated with 1.25 µM concentration of free DOX and 
DOX-conjugated particles for 24 hours. Subsequently, the cells were treated with reagents 
of LDH-Glo™ Cytotoxicity Assay (Promega, Wisconsin, MI, USA) as per the 
manufacturer’s instructions. The luminescence of the treatment groups was measured using 
TECAN plate reader. 
3.13.2 Apoptosis Evaluation- Acridine Orange/Ethidium Bromide (AO/EB) Staining 
DOX is known to induce apoptosis as one of the pathways to induce the 
cardiotoxicity. Therefore, to evaluate the influence of DOX-conjugated particles in 
providing protection against DOX induced apoptosis in H9C2 rat cardiomyoblasts, 
acridine orange (AO) and ethidium bromide (EB) double florescent staining method as 
reported previously was used [69]. Briefly, H9C2 cells were seeded at a density of 8.0×104 
cells/well in a 24 well tissue culture plate and incubated overnight at 37°C/5% CO2 
overnight. Post incubation, the cells were treated with free DOX and DOX-conjugated 
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particles at a concentration of 1.25 µM for 24 hours. After the treatment period, cells were 
washed twice with PBS pH 7.4 and stained using 200 µL of 1:1 AO:EB at concentration 
of 100µg/mL each. The cells were incubated with dyes in dark for 30 minutes and imaged 
at 20X magnification using EVOS-FL florescence microscope (Thermo Fisher Scientific, 
Waltham, MA, USA) 
3.15 Statistical Analysis 
All the results are  presented as mean±SD unless otherwise stated. Statistical 
significance was determined using student’s t-test, one-way ANOVA and Tukey’s post-
hoc multiple comparison by GraphPad Prism 6.01 (San Jose, CA, USA). p<0.05 or less 




4.0 Results and Discussion 
4.1 Particle Fabrication and Morphology of Particles 
Three different sizes of polystyrene particles were used to prepare elongated rod-
shaped (fiber like) particles. The rod-shaped particles were successfully fabricated using 
one-dimensional film stretching as mentioned in the methods section. The particles were 
imaged using SEM as seen in Figure 6, spherical particles over various sizes were 
successfully transformed to rod shaped particles having varied aspect ratios. Aspect ratio 
(AR) is defined as the ratio of the length of major axis of particles to the length of minor 
axis of the particles. As seen from Table 1 and Figure 6, stretching of 0.5µm particles to 
3 folds resulted into short rod (SR) shaped particles with major axis of 1.4 ± 0.1 µm and 
minor axis 0.3 ± 0.0 µm resulting into AR of 4.08 ± 0.17. Upon further stretching the 
particles to 6-fold, of 0.5µm particles produced particles long rods (LR) having major axis 
length of 1.9±0.2 µm and minor axis length of 0.3 ± 0.0 µm possessing an AR value of 
6.56 ± 0.60. As observed increase in stretching length from SR to LR resulted into increase 
in AR value. Similarly, polystyrene particles of 6.0 µm equivalent diameter upon 3 folds 
stretching resulted into SR with 9.1±0.9 µm (major axis length) and 1.7±0.3 µm (minor 
axis length) causing an AR value of 5.4±0.8. Further, LR of 6.0 µm equivalent diameter 
displayed 13.7±1.6 µm (major axis length) and 1.5±0.4 (minor axis length) resulting into 





Figure 6: Representative scanning electron microscopy (SEM) micrographs of particles 
obtained by stretching microparticles of various sizes. Scale bar= 10µm  
 Table 1: Calculated particle size of stretched particles using Image J software. Data 
represents mean±SD for 3 individual images with n=30 for each sample. 




 (Major axis/Minor axis) 
0.5µm-SR 1.4 ± 0.1 0.3 ± 0.0 4.1 ± 0.2 
0.5µm-LR 1.9 ±  0.2 0.3 ± 0.0 6.6 ± 0.6 
6.0µm-SR 9.1 ± 0.9 1.7 ± 0.3 5.4 ± 0.8 
6.0µm-LR 13.7 ± 1.6 1.5 ± 0.4 9.1 ± 1.4 
10µm-SR 22.1 ± 3.3 7.1 ± 0.9 3.3 ± 0.5 




Stretching of 10.0 µm particles to 3 folds resulted into fabrication of SR particles 
with 22.1 ± 3.3 µm major axis length and 7.1 ± 0.9 µm of minor axis length accounting for 
AR value of 3.3 ± 0.5. Similarly, stretching to 6 folds formed LR particles with 32.2 ± 3.2 
µm (major axis length) and 5.6 ± 0.9 µm (minor axis length) resulting into 5.8 ± 1.1 AR 
value as can be seen in Table 1 and Figure 6. Interestingly it was observed that AR values 
of both SR and LR particles stretched from10.0 µm equivalent diameter size was found to 
be less than their respective counterparts of 6.0 µm and 0.5 µm equivalent diameter size 
particles. This reduction in the AR value of 6.0 and 10.0 µm equivalent diameter particles 
as against 0.5 µm can be attributed to the crosslinking of the polystyrene particle; as these 
large sized particles were reported to be crosslinked with divinylbenzene (Manufacturer 
protocol, Polysciences Inc.). Polymer crosslinking is known to restrict the rotational 
motion of the polymer molecules resulting into increase in the glass transition temperature 
of polymer which increases the rigidity of the polymer [70]. The increased rigidity of the 
polymer hampers the flexibility of the particle to be stretched and thus resulting into lower 
AR values. These results infer that particle of various size can be successfully transitioned 
from spherical to rod shape by employing the stretching method. 
4.2 Conjugation of Drug with Particles 
DOX was chosen as the model drug for conjugation with the particles due to the 2 
major reasons : 1) widely explored conjugation chemistry and 2) inherent florescence 
which can be used in the in-vitro studies. The fabricated particles were conjugated with 
DOX using EDC-NHS chemistry and the amount of DOX-conjugated was analyzed by 
measuring UV absorbance.  As seen in Figure 7, the amount of DOX-conjugated to 
particles of 0.5 µm size was found to be 454.6 ± 2.0 µg of DOX/mg of particles (Sph), 
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469.1 ± 5.3 µg of DOX/mg of particles (SR) and 425.8 ± 5.5 µg of DOX/mg of particles 
(LR). Upon increasing the particle size from 0.5 to 6.0 µm, the amount of DOX-
conjugated/mg of particles remained almost same as in Figure 7.   
 
Figure 7: Characterization of DOX conjugation to various 10µm particles. (A) amount of 
DOX-conjugated to various particles expressed as µg of DOX/mg of particles. Data is 
represented as mean±SD for n=3 experiments. 
6.0µm-Sph showed 400.1 ± 2.6 µg of DOX/mg of particles while stretched particles 
displayed 386.2 ± 6.5 µg of DOX/mg of particles (6.0µm-SR) and 367.7 ± 1.7 µg of 
DOX/mg of particles (6.0µm-LR). Further increasing the particle size to 10µm, 
conjugation of DOX was found to be unaffected with 10µm-Sph illustrating 425.5 ± 3.3 
µg of DOX/mg of particles. The stretched particles 10µm-SR displayed 406.1 ± 1.2 µg of 
DOX/mg of particles while 10µm-LR demonstrated 399.0 ± 1.9 µg of DOX/mg of particles 
being conjugated (Figure 7). The amount of DOX-conjugated to carboxylic acid groups 
functionalized on particles across various size and shape almost remained similar. This 
indicates that carboxylic acid functionalized on the surface of polystyrene particles remain 
unaffected by the stretching owing to its hydrophilic nature and thus are believed to be 
readily available for conjugation. The amount of carboxylic acid groups available for 
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conjugation on particles is attributed to be dependent on the total particle volume indicating 
that increase in size of particle causes increase in amount of carboxylic acid groups [71]. 
Therefore, to equalize the amount of carboxylic acid available for conjugation amongst the 
particles various size and shapes, we have used a constant total mass of particles for 
conjugation reaction. This  values of µg of DOX/mg of particles were found to be almost 
equivalent as seen in Figure 7. 
4.3 Characterization of DOX Conjugation 
4.3.1 DSC Studies 
Calorimetric studies was performed to evaluate the conjugation of DOX with the 
particles. Figure 8A represents the thermogram of the analyzed samples, wherein DOX 
shows a sharp endothermic peak at  206.2°C representing the melting of DOX as also 
reported in literature [72,73]. Thermogram of blank particles displays a small endothermic 
peak at 103.2°C representing the glass transition (Tg) temperature of polystyrene [74,75]. 
Thermal study result of physical mixture of DOX and blank particles demonstrate first 
endothermic peak at 105.3°C due to Tg of blank particles and second at 198.4°C 
representing melting point of DOX as in Figure 8A. In case of all the DOX-conjugated 
particles, the characteristic peak of DOX was found to be absent, indicating that pure DOX 
was not present in the conjugated particles and was removed during washing steps 
suggesting that DOX present in the formulation is bound to the particles. These results also 














Figure 8: Characterization of DOX conjugation to various 10µm particles. (A) 
Thermograms of samples analyzed using differential scanning calorimetry (DSC). (B) 
Spectra of samples analyzed using FT-IR also a representative magnified image of spectra 




4.3.2 FT-IR studies 
Thermal spectra of analyzed samples are displayed in Figure 8B wherein DOX 
displays several characteristic peaks at 3315 cm-1 (-N-H2 stretching), 2916 and 2898 cm-1 
(-C-H stretching of phenol rings), 1730 cm-1 (-C=O ketone stretching and C-H2 bending), 
1617 cm-1 (-CO-H bending), 1580 cm-1 (-C=O quinone stretching), 1525 cm-1 (out of pane 
vibration of -N-H2) and 881 cm-1 (-C-N bending) [76–78]. Polystyrene particles 
demonstrated peaks at 3106 cm-1, 3079 cm-1  and 3026 cm-1 (C-H stretching of aromatic 
rings and -O-H stretching of carboxylic acid), 2930 cm-1 and 2849 cm-1 (-CH2- stretching), 
1620 cm-1 ,1511 cm-1 and 1470 cm-1 (C=C stretching of aromatic rings) [79,80] (Figure 
8B). Analysis of all the three DOX-conjugated particles (10µm-Sph, 10µm-SR and 10µm-
LR) demonstrated majority of characteristic peaks of DOX at ~ 3315 cm-1, 2916 cm-1, 1730 
cm-1 and 1580 cm-1 indicating the presence of DOX in the conjugated particles. However, 
as seen in Figure 8B conjugation of DOX to polystyrene resulted into substitution of 1525 
cm-1 (out of pane vibration of -N-H2) of DOX with peak at 1509 cm-1 (10µm-Sph), 1502 
cm-1 (10µm-SR) representing amide II vibrations of -N-H and -C-N stretching, indicates 
the involvement of -NH2 group to form the -CONH bond [81,82]. These FT-IR results 
indicates successful conjugation of DOX to the polystyrene particles via amide bond 
linkage between the carboxylic acid (-COOH) groups of polystyrene particles and amine 
(-NH2) group of DOX  
4.4 In-vitro Pulmonary Deposition Behavior 
The aerodynamic behavior of the fabricated particles were assessed using NGI 
measured in terms of MMAD and % FPF. The data of the impact of particle shape and size 
on in-vitro pulmonary deposition is shown in Table 2.   
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Table 2: Aerosolization properties of various microparticles calculated in terms of MMAD 
and % FPF. Data is represented as mean±SD for n=3 experiments. *p<0.05, ** p<0.01, 
**** p<0.001 and **** p<0.0001.  
Sample  MMAD % FPF 
0.5µm-Sph 4.5 ± 0.3 77.2 ± 5.0 
0.5µm-SR 4.2 ± 0.5 74.2 ± 0.7 
0.5µm-LR 4.4 ±  0.4 79.5 ± 5.7 
6.0µm-Sph 5.6 ± 0.1 61.7 ± 2.1 
6.0µm-SR 4.3 ± 0.2** 76.5 ± 4.9* 
6.0µm-LR 4.7 ± 0.1** 76.2 ± 1.1* 
10µm-Sph 8.2 ± 0.8 44.7 ± 5.7 
10µm-SR 4.2 ± 0.6**** 89.5 ± 9.6*** 
10µm-LR 3.4 ± 0.1**** 95.5 ± 0.6**** 
 
Aerodynamic parameters of 0.5 µm particles assessed using NGI are shown in 
Table 2. All the three particles; 0.5µm-Sph, 0.5µm-SR and 0.5µm-LR demonstrated 
MMAD ~4.5 along with no significant difference observed in % FPF value reported to be 
>75%. Increase in the particle size from 0.5 µm to 6.0 µm resulted into increase in the 
MMAD of 5.6 ± 0.1 (for 6.0µm-Sph) along with % FPF value of 61.7 ± 2.1 indicating 
maximum deposition occurring the proximal region of the respiratory tract. However, 
transition of particle shape from spheres to rod resulted into significant (p<0.01) reduction 
in MMAD value as 4.3 ± 0.2 for 6.0µm-SR and 4.7 ± 0.1 as observed for 6.0µm-LR (Table 
2). On the other hand, % FPF values for 6.0µm rod shaped particles were found to be 
significantly (p<0.05) increased as against the spherical particles as seen in Table 2. 
6.0µm-SR resulted into 76.5 ± 4.9 % FPF value and 6.0µm-LR displayed 76.2 ± 1.1 % FPF 
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value. Similarly,  MMAD value for 10µm-Sph as reported in Table 2 indicated a high 
MMAD value of 8.19±0.8 µm while the stretched particles demonstrated a significantly 
(p<0.0001) lower MMAD values of 4.2 ± 0.6 µm for 10µm-SR particles and 3.4 ± 0.1 µm 
for 10µm-LR particles, respectively. Upon comparing the % FPF value (Table 2), 10µm-
Sph displayed ~45% while rod-shaped particles demonstrated significant (p<0.0001) 
increase in % FPF with ~90% for 10µm-SR and ~95% for 10µm-LR particles. This 
increase in % FPF indicates that most of the emitted dose will be deposited in the respirable 
region of the lungs which comprises of the bronchi-alveolar region.   
The deposition of 10µm DOX-conjugated particles on various stages of NGI are 
represented in Figure 9A. As can been seen from the Figure 9A, for 10µm-Sph particles, 
the deposition was seen mostly in stage 1 (~4 µg), stage 2 (~ 6 µg), stage 3 (~5 µg) and 
stage 4 (~3 µg) while ≤ 1 µg DOX deposition was observed from stage 5 to stage 8. This 
indicated that deposition of 10µm-Sph predominantly occurred above the bronchi-alveolar 
regions. The stretched particles: 10µm-SR and 10µm-LR on the other hand showed 
minimal deposition at stage 1 and 2 (≤ 1 µg). The deposition of stretched particles, both 
SR and LR increased dramatically stage 3 onwards. Maximum deposition of particle for 
stretched particles was observed in stage 5 wherein ~ 22 µg of DOX was quantified for 
10µm-SR and ~28 µg DOX for 10µm-LR particles. At stage 6, the deposition of DOX 
decreased to ~16 µg for 10µm-SR while the reduction in deposition behavior of 10µm-LR 
particles was mild with ~25 µg DOX observed for 10µm-LR. The deposition of 10µm-LR 
particles as could be seen in Figure 9A continued until stage-8 with ~5 µg DOX observed 














Figure 9: (A) Aerodynamic distribution pattern of various 10µm particles at different 
stages of Next Generation Cascade Impactor (NGI) expressed as DOX Deposition (µg) at 
each stage. (B) % Cumulative deposition plotted against effective cut-off diameter 
(microns) to determine deposition impact due to difference in particle shape of 10µm 





Since majority of deposition for 10µm-SR and 10µm-LR stretched particles beyond 
stage 3 (representing bronchi-alveolar region), it can be confirmed that change in the shape 
of the particles enhance the deposition of particles in the deeper lungs. The % cumulative 
deposition plot as in Figure 9B indicated that 50% of the cumulative dose for 10µm-Sph 
deposited at the effective cut-off aerodynamic diameter of 5.57 µm. The stretched particles 
demonstrated a significantly (p<0.0001) lower effective cut-off aerodynamic diameter for 
50% cumulative deposition: 2.53 µm for 10µm-SR particles and 2.26 µm for 10µm-LR 
particles (Figure 9B). These results support the fact that rod shaped particles (stretched 
particles) improve the deposition behavior of the particles as against the spherical particles 
resulting into maximum deposition at lower aerodynamic diameter. This can be attributed 
to the better propulsion of rod-shape particles down the respiratory tract after aligning 
themselves with the air flow [83]. Several computational fluid dynamics simulation models 
have predicted the deposition of fiber (elongated rod shaped; AR>3) vs sphere particles in 
the lungs, wherein elongated particles streamlines themselves to the air flow and therefore 
tend to deposit in the peripheral airways  [83–85]. Particle shape is also reported to 
influence the mechanism of particle deposition in lungs; wherein the spherical particles 
tend to deposit predominantly by inertial impaction (for MMAD>5 µm), gravitational 
sedimentation (for MMAD 1 to 5 µm) or diffusion (for MMAD ≤0.5 µm) [34,37,86]. While 
the rod-shaped particle on the other hand deposit by interception, wherein the fiber like 
particles comes in close contact to the surface such that it touches the surface which would 
have been missed by the center of the mass [36]. Increase in the length of particles results 
into increase in the deposition of particles via interception which allows the particles to 
streamline with the airflow and travel to the distal airways in the alveolar region [87]. This 
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justifies the improved aerodynamic behavior of rod-shaped particles against spheres and 
amongst the rod-shaped particles, LR better than SR. Therefore, the results of in-vitro 
pulmonary deposition behavior have been successful in supporting the hypothesis that 
changing the shape of spherical particles to rod-shape results into deeper lung deposition 
of particles. 
4.5 In-vitro Release of DOX-conjugated Particles 
The release of DOX from conjugated polystyrene particles was analyzed in buffers 
at pH 7.4 mimicking physiological conditions and pH 5.5 representing lysosomal vesicles 
and microenvironment of cancer cells [88,89]. As seen in Figure 10, no burst release of 
DOX was observed in the in-vitro release study. The release of DOX was observed to be 
pH dependent which indicated that release of DOX was faster at lower pH value of 5.5 as 
compared to higher pH 7.4. DOX-conjugated particles upon incubation at pH 5.5 released 
about 45.2 ± 2.8 % of DOX from 10µm-Sph particles, 43.8 ± 1.3 % DOX from 10µm-SR 
particles and 45.7 ± 1.3% DOX from 10µm-LR particles after 5 days (Figure 10). While 
significantly (p<0.0001) small amount of DOX was found to be released at physiological 
pH 7.4 due to slower hydrolysis of the amide bond [81]. The % drug released after 5 days 
incubation of 10µm-Sph particles was 18.9 ± 2.3% while 10µm-SR particles displayed 
18.7 ± 3.0% and 10µm-LR particles showed 18.7 ± 3.7% cumulative release of drug 
(Figure 10). On the other hand, increased release of DOX from the particles at acidic pH 
is known to be mediated cleavage of the amide bond due to acid hydrolysis resulting into 
subsequent release of DOX in the media [81,88]. These results are in accordance to other 
studies wherein slower release of DOX at pH 7.4 indicated enhanced stability of amide 
conjugated DOX particles and its slower hydrolysis kinetics at normal physiological 
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conditions [81,89–91]. In addition, the slower release of DOX at physiological pH supports 
the use of these conjugated particles as effective delivery carrier due to reduced loss of 
DOX while reaching the site of action resulting into low off-target side effects and 
increased tumor accumulation [92,93].  
 
Figure 10: In-vitro drug release profile of DOX from various 10µm particles; 10µm-Sph, 
10µm-SR and 10µm-LR evaluated at pH 7.4 and pH 5.5. Data represents mean ± SD (n=3).  
4.6 Stability Studies 
Stability of 10µm DOX-conjugated particles were tested after storing for 15 days 
at two different conditions: 1) storage conditions represented by 4°C and 2) accelerated 
stability conditions represented by 40°C and 75% relative humidity (RH). The stability was 
assessed in terms of particle shape, particle size and the amount of drug conjugated. Figure 
11A represents the SEM images of the particles, wherein there was no change observed in 
the shape of the particles when stored at accelerated conditions as against normal storage 
conditions. This can be attributed to the high glass transition temperature (110°C) of the 
polystyrene particles remaining unaltered at the accelerated conditions (40°C/75% RH) 
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and thereby maintain the same shape. Furthermore, the size of the stretched particles were 
measured using ImageJ software to evaluate if any existed in the particles. As seen in 
Figure 11B, the major axis of the 10µm-SR particles at 4°C was found to be 25.2 ± 1.2 
µm  (vs. 24.6 ± 1.9 µm at 40°C/75%RH) and minor axis of 24.6 ± 1.9 µm (vs. 7.9 ± 0.9 
µm for 40°C/75%RH). The aspect ratio of particles also showed non-significant difference 
with 3.5 ± 0.4 at normal conditions vs. 5.9 ± 0.9 at accelerated condition. Similarly, 10µm-
LR particles also displayed non-significant changes in particle size parameters as in Figure 
11B. The length of major axis at 4°C was found to be 36.2 ± 2.0 µm while at 40°C/75%RH 
it was reported to be 36.7 ± 2.5 µm. The minor axis of 10µm-LR particles at normal 
conditions was found to be 6.1 ± 0.9 µm at vs. 5.9 ± 0.9 µm at accelerated conditions. Upon 
analyzing the aspect ratio values, no significant differences were observed between 4°C  
with 6.4 ± 1.0 compared to 6.3 ± 1.2 at 40°C/75%RH (Figure 11B).  
Furthermore, the amount of conjugated to the particles was analyzed at the end of 
the stability period. As seen in Figure 11C, 10µm-Sph displayed 426 ± 10µg of DOX/mg 
of particles at 4°C as against 421 ± 9 µg of DOX/mg of particles at 40°C/75%RH. 10µm-
SR particle demonstrated ~430 mg of µg of DOX/mg of particles at both the stability 
conditions. Similarly, 10µm-LR particle displayed non-significant changes with ~460 µg 
of DOX/mg of particles at both the stability conditions. This non-significant difference in 
the amount of conjugated drug present at both the stability conditions can be attributed to 
the stable amide bond conjugation between DOX and the carboxylic acid of the polystyrene 
particles which remains unaffected at the increased temperature [94]. These results indicate 









Figure 11: Stability of various 10µm particles evaluated at two different conditions; 4°C 
and 40°C/75%RH, after 15 days storage evaluated for changes in morphology, particle 
size, and amount of drug conjugated.  (A) Stability evaluated in terms of morphological 
changes of particles represented by respective SEM micrographs. (B) Stability evaluated 
in terms of major axis length, minor axis length and aspect ratio of particles and (C) 
Stability evaluated in terms of µg of DOX/mg of particles present at the end of 15 days. 
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4.7 Investigating Escape of Particles by Macrophages 
4.7.1 Cellular Uptake 
The cellular uptake of DOX-conjugated spherical and stretched particles was 
analyzed using fluorescent microscope after incubation of particles for 3 hr. As seen in 
Figure 12A, DOX demonstrated enhanced internalization with DOX florescence (Red) 
being overlapped over the cellular nuclei (DAPI- blue fluorescence). This indicates that 
free DOX was readily localized in the cell nucleus of RAW 264.7 cells. For 10µm-Sph 
particles, it can be observed that DOX was conjugated to the spherical particles and 
distributed in the cytoplasm surrounding the nuclei of RAW 264.7 cells. The stretched 
particles 10µm-SR displayed presence of some DOX particles in the cytoplasm of the cells, 
however the florescence intensity of DOX was comparatively less than the spherical 
particles indicating reduced cellular uptake of the 10µm-SR stretched particles (Figure 
12A). For 10µm-LR particles as in Figure 12A, there was minimal DOX florescence 
observed in the cytoplasm or nuclei of the cells suggesting impact of particle shape on the 
cellular uptake by the macrophage cells. Based on these results, it can be inferred that 
change in the shape of the particles may influence the uptake of the particles by 
macrophages.  
The intracellular uptake of free DOX and DOX-conjugated particles was analyzed 
by quantifying the florescence of DOX. As demonstrated in Figure 12B, free DOX 
displayed the highest florescence intensity at both the incubation time; 1 hr. and 3 hrs. 
Furthermore, free DOX demonstrated significantly (p<0.001) stronger florescence 












Figure 12: In-vitro cellular uptake studies of various 10µm particles. (A) Florescent 
images of DOX, 10µm-Sph, 10µm-SR and 10µm-LR in RAW 264.7 macrophages after 3 
hrs. incubation. The inset images represents magnified image of the outside image. 
Representative images from n = 3 experiments. Scale bar = 100 µm (B) Quantitative 
determination of intracellular DOX after 1 hr. and 3 hrs. incubation in RAW 264.7  cells 
represented as florescence intensity. Data represent mean ± SD (n=3). *p<0.05, ** p<0.01, 
**** p<0.001 and **** p<0.0001. 
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 Amongst, 10um particles Sph demonstrated significantly higher florescence 
intensity after 1 hr. incubation ~1.7-folds (p<0.05) and ~2.4 folds (p<0.01) than 10µm-SR 
particles and 10µm-LR particles, respectively. However, at 1 hr. incubation there was no 
significant difference observed between the fluorescence intensity of 10µm-SR particles 
and 10µm-LR particles. The florescence intensity of 10µm-sphere particles after 3 hrs. 
incubation displayed ~1.4 folds (p<0.01) increased florescence intensity as against 10µm-
SR particles while ~2.4 folds (p<0.001) increase as compared to 10µm-LR particles as in 
Figure 12B. Additionally, 10µm-SR particles displayed significantly (p<0.01) higher 
fluorescence of ~1.5 folds when compared to 10µm-LR particles. The results of this study 
are also corroborated by the fluorescence imaging results depicting the escape of 10µm-
LR particles from macrophage uptake.  
The enhanced internalization of free DOX in the macrophages can be attributed to 
the rapid passive diffusion mechanism of DOX [95,96]. Whereas internalization of DOX-
conjugated 10µm particles (both spheres and stretched particles) may undergo energy 
dependent uptake pathway such as phagocytosis and therefore display comparatively 
reduced uptake as against DOX [97]. The results further demonstrate that change in the 
shape of the particle from sphere to rod results into reduced uptake by macrophages. This 
in accordance to several studies reporting that macrophage uptake is highly influenced by 
the shape of particles wherein spherical particles are readily internalized as compared to 
non-spherical shape [61,98,99]. This effect is further escalated for particles with higher 
aspect ratio, wherein macrophages are not able to completely engulf such particles due to 
incomplete formation of actin pseudopods around the particles resulting into reduced 
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cellular internalization [99,100]. Therefore, particles with higher aspect ratio have higher 
possibility to escape the macrophage uptake which in our case is 10µm-LR particles.  
4.7.2 Cytotoxicity Assessment on Macrophages 
Cytotoxicity of free DOX and DOX-conjugated 10µm particles (Sph, SR, and LR) 
was assessed on RAW 264.7 cells using MTT assay after 24 hrs. and 48 hrs. incubation 
time. Figure 13A represents the % cell viability of RAW 264.7 cells after 24 hrs. treatment 
wherein free DOX demonstrated highest cytotoxicity of macrophages amidst all the 
treatment group with an IC50 value of 1.06 ± 0.1µM. The DOX-conjugated spherical 
particles at 5µM concentration displayed ~70% cell viability while stretched particles SR 
and LR displayed ~75% cell viability (Table 3). Further, DOX displayed time dependent 
cytotoxicity on macrophages as can be observed in Figure 13B and Table 3 with IC50 
value of 0.08 ± 0.03 µM. The treatment with DOX-conjugated 10µm-Sph displayed ~28 
folds increase in IC50 value; 2.8 ± 0.8 µM as compared to DOX. The stretched 10µm-SR 
particles displayed ~31 folds increase in IC50 value as compared to free DOX and ~1.1 
folds increase against 10µm-Sph with an IC50 of 3.1 ± 0.1 µM. Treatment with 10µm-LR 
particles resulted into significant (p<0.01) ~71 folds increase in IC50 against DOX  with 
IC50 of 7.5 ± 3.1 µM. Additionally, 10µm-LR particles displayed ~2.7 folds (p<0.05) 
increase in IC50 as against 10µm-Sph and  ~2.5 folds (p<0.05) increase against10µm-SR 
particles (Figure 13B and Table 3). Based on the cytotoxicity results, treatment group can 
be in the ranked in the following order for displaying cytotoxicity against RAW 264.7 
macrophages: DOX>10µm-Sph>10µm-SR>10µm-LR. These outcomes are in accordance 
the results of cellular uptake wherein DOX is demonstrated to be readily internalized by 


















Figure 13: In-vitro cytotoxicity studies of various 10µm particles in RAW 264.4 cells 
determined using MTT assay. (A)  Cytotoxic potential of DOX conjugated DOX-
conjugated 10µm particles evaluated after 24 hrs. incubation (B) Cytotoxic potential of 
DOX conjugated DOX-conjugated 10µm particles was evaluated after 48 hrs. incubation 
(C) Blank particle cytotoxicity evaluated in RAW 264.7 cells after 24 hrs. incubation and 
(D) Blank particle cytotoxicity evaluated in RAW 264.7 cells after 48 hrs. incubation. 







Amongst DOX-conjugated 10µm particles, stretched particle with highest aspect 
ratio i.e., 10µm-LR particles escape the cellular uptake by macrophages and thereby 
demonstrate significantly reduced cytotoxicity. The cytotoxicity of blank particles was also 
assessed in Raw 264.7 cells after 24 hrs. and 48 hrs. incubation. As seen in Figure 13C, 
after 24 hrs. of incubation all the blank particles demonstrated >85% cell viability. Similar 
results were observed after 48 hrs. incubation of particles as in Figure 13D, wherein all 
the particles displayed >80% cell viability against the macrophages indicating that the 
particles were safe against the RAW 264.7 cells. These findings indicate that the 
cytotoxicity of DOX-conjugated particles observed in macrophages is because of DOX 
from the conjugated particles internalized by the cells and not due to the polystyrene 
particles. 
Table 3: IC50 values of different treatment groups in RAW 264.7 cells calculated from 






4.8 Evaluating Impact of Particle Shape Against Small Cell Lung Cancer (SCLC) 
SCLC was chosen as a model disease to predict the impact of particle shape of 
delivery carriers on the effectiveness of treatment. Lung cancer is known to be second most 
Treatment Group IC50 value (µM) 
DOX 0.1 ± 0.0  
10µm-Sph  2.8 ± 0.8 
10µm-SR 3.1 ± 0.1 
10µm-LR  7.5 ± 3.1 
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common cancer accounting for ~2 million death worldwide [101]. SCLC represents about 
13% to 15% of the total lung cancer cases and is referred as the most aggressive form of 
lung cancer [102]. In this project, multidrug (including DOX) resistant H69AR SCLC cells 
were used to evaluate the efficacy of treatment against the tumorigenic property of SCLC 
cells. The reason to use DOX resistant H69AR cell line was the extremely low IC50 of DOX 
~0.7 µM in the non-drug resistant variant H69 [103,104]. We believed that treatment of 
cells with DOX-conjugated particles at such low concentration may not will lead to 
extremely small number of particles being exposed to cells which may not truly reflect the 
effectiveness of particle shape on treatment against tumorigenic activity of cells 
4.8.1 Cellular Uptake 
The uptake of DOX-conjugated particles was assessed in DOX resistant SCLC cells 
after incubation for 3 hours using florescence microscope. As seen in Figure 14A, DOX 
(red florescence) was seen to be readily up taken by the cells and was localized in the 
nucleus (blue florescence). When DOX-conjugated particles were incubated with the cells, 
the florescence was observed in the cytoplasm of the cells unlike the free DOX which was 
localized in nucleus. The stretched particles displayed higher DOX florescence in the 
cytoplasm around the cells as compared to the 10µm sphere particles. Amongst the 
stretched particles, 10µm-LR particles displayed greater florescence than 10µm-SR 






















Figure 14: Cellular uptake studies of  DOX-conjugated 10µm particles in H69AR cells 
after 3 hrs. incubation. Florescent images of DOX, 10µm-Sph, 10µm-SR and 10µm-LR in 
H69AR cells. Representative images from n = 3 experiments. Scale bar = 100 µm (B) 
Quantitative determination of intracellular DOX after 3 hrs. incubation in H69AR cells 





In addition to florescence imaging, we have also evaluated cellular uptake by 
quantifying the florescence of DOX internalized by the cells after incubating for 3 hours.  
Figure 14B demonstrates the results of cellular uptake determined by measuring the 
florescence quantification, wherein free DOX showed highest florescence intensity 
amongst all the treatment group. The florescence intensity of DOX was found to be 
significantly (p<0.01) higher than 10µm-Sph particles and 10µm-SR particles. DOX-
conjugated particles showed shape dependent impact on the cellular uptake with 10µm-
sphere particles showing the minimal florescence intensity. The increase in aspect ratio led 
to increase in the florescence intensity with 10µm-SR particles showing ~1.2 folds increase 
as compared to 10µm-sphere particles. Similarly, 10µm-LR particles showed ~1.4 folds 
significant (p<0.05) increase in florescence intensity compared to spherical particles 
(Figure 14B).  
These results are in accordance with the cellular uptake florescence imaging data 
indicating shape dependent effect of particles on uptake by SCLC cells wherein elongated 
particles are readily internalized compared to spherical particles. The increased uptake of 
DOX in the obtained results can be attributed to the gradient mediated passive diffusion 
while the DOX-conjugated particles undergo phagocytosis by the SCLC cells. These 
findings are in accordance to the previously published studies where microparticles with 
higher AR values are internalized faster by cancer cells [105,106].. Increase in the aspect 
ratio of conjugated particles resulted in increased uptake by cancer cells [105,107]. This 
can be because of increased fluidity of cancer cells’ plasma membrane due to varied lipid 
metabolism resulting into improved uptake of the stretched particles (elongated with sharp 
ends) as against spherical particles unlike what was observed in the normal cells like 
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macrophages [107–109]. These results confirmed that increase in aspect ratio of particles 
results into improved uptake of particles by SCLC cells.  
4.8.2 Cytotoxicity assessment in SCLC cells 
The cytotoxicity of free DOX and DOX-conjugated particles was evaluated by 
MTT assay after incubating H69AR cells for 72 hours over concentration range of 0.2 to 
30 µM. Results as shown in Figure 15A indicate that free DOX has the highest cytotoxicity 
over the concentration range tested with an IC50 value of 8.3 ± 2.3 µM (Figure 15B). 
Treatment with 10µm-Sph showed a significant (p<0.001) ~2.6 folds reduction in the 
cytotoxicity against H69AR cells with an increased IC50 value of 21.6 ± 1.8 µM as 
compared to free DOX. Shape dependent effect was observed in the cytotoxicity of DOX-
conjugated particles, wherein rod-shaped particles demonstrated better cytotoxicity against 
SCLC cells as compared to spherical particles. 10µm-SR particles showed improved 
cytotoxicity with reduced IC50 value of 18.1 ± 2.4 µM as against 10µm-Sph (Figure 15A 
and 15B). While treatment with 10µm-LR particles showed significant (p<0.05)1.4 folds 
reduction in IC50 value with 15.8 ± 2.5 µM as compared to 10µm-Sph particles, indicating 
superior cytotoxic effect against H69AR cells. These results are also supported by the 
cellular uptake results which infer that change in the shape of particles resulting into 
increased aspect ratio imparts improved cytotoxicity against SCLC cells. Blank particles 
cytotoxicity was also evaluated on H69AR cells after incubation for 72 hours. As can be 
seen in Figure 15C, all the three particles demonstrated >85% cell viability over the 
concentration range of 0.2 µM to 30 µM concentration. These results confirm that the blank 
particle are safe against H69AR cells and the cytotoxic effects observed is due to the DOX 



















Figure 15: Cytotoxicity studies of various treatment groups after 72 hrs. incubation in 
H69AR cells. (A) Cytotoxic potential of DOX, and DOX-conjugated 10µm-Sph, 10µm-
SR and 10µm-LR expressed as % cell viability. (B) IC50 values of DOX DOX and DOX 
conjugated particles calculated from the experimental cytotoxicity data (C) Cytotoxic 
potential of blank 10µm-Sph, 10µm-SR and 10µm-LR particles expressed as % cell 




4.8.3 In-vitro Tumor Simulation Studies 
The monolayer cell culture studies (2D) does provide valuable information about the 
behavior of particles with cells; however, it does not truly reflect the in-vivo conditions. 
Therefore, to better assess the influence of particle shape in tumor conditions we performed 
in-vitro tumor simulation studies also known as 3D spheroid cell culture studies which 
simulates physiological tumorigenic conditions and provide relevant understanding about 
the therapeutic behavior of treatment as compared to the traditional monolayer studies 
[110,111].  3D spheroid tumor models have been extensively explored in high throughput 
screening of lead compounds, evaluating the drug safety and efficacy profile, assessing the 
development of drug resistance and anti-tumorigenic activity of the delivery systems [112–
114].  In this study, we have utilized in-vitro tumor simulation studies to evaluate the 
particle shape dependence on the anti-tumor activity of DOX-conjugated particles against 
H69AR SCLC cells. The study was performed at two different doses: 1) single dose study 
involves treatment to the cells only once at the start of experiments and 2) multiple dose- 
involves treatment at every 72 hours until the end of study. The anti-tumor efficacy of the 
treatment against the SCLC cells was measured in terms of spheroid volume, % cell 
viability in spheroids and imaging the live cells present in the spheroids using live-dead 
















Figure 16: Effect of single dose treatment on tumorigenic activity of H69AR cells grown 
as 3D spheroids simulating in-vivo tumor conditions. (A) Representative images of 
spheroids demonstrating suppression in tumor growth at days 0, 3 and 6. Scale bar = 200 
µm (B) Quantitative representation of anti-tumor activity of treatment expressed as 
spheroid volume (mm3) versus time (days) for single dose treatment.  Data represent 




A) In-vitro Tumor Simulation Studies- Single Dose 
Figure 16A represents the tumor images of single dose treatment groups captured at 
different time intervals. As can be seen from the figure, control (untreated) group displayed 
uncontrolled tumor growth resulting into 40.7 ± 2.9 mm3 volume of the spheroids at Day 
6 (Figure 16B). Treatment with DOX and DOX-conjugated particles resulted into 
significant inhibition of tumor growth. DOX treatment resulted into inhibition in tumor 
growth along with loss of tumor integrity at Day 6 (Figure 16A) and a significant 
(p<0.001) 4.6 folds reduction in spheroid volume (8.8 ± 0.4 mm3) as compared to control 
(Figure 16B). On the other hand, DOX-conjugated particles showed shape dependence 
anti-tumor effect against the H69AR spheroids wherein 10µm-Sph showed significant 
(p<0.001) 1.6 folds reduction in tumor growth as compared to control with tumor volume 
of 24.9 ± 0.5 mm3 on day 6 and no influence on tumor integrity (Figure 16A and 16B). 
While  rod-shaped particles demonstrated superior tumor growth inhibition of SCLC 
spheroids as against spherical particles. 10µm-SR particles showed ~3.5 folds significant 
inhibition (p<0.001) of spheroid volume (7.2 ± 0.7 mm3) and loss of tumor integrity at day 
6 when compared to 10µm-Sph (Figure 16A and 16B). Treatment with 10µm-LR particles 
resulted into loss of tumor integrity and enhanced anti-tumor activity with spheroid volume 
of 5.6 ± 1.1 mm3 showing ~4.4 folds and 1.6 folds reduction in spheroid volume when 
compared to 10µm-Sph (p<0.0001) and free DOX (p<0.05) respectively. These results 
signify the shape dependent impact of particles on the anti-tumorigenic activity of DOX 
against H69AR tumors with LR particles demonstrating the highest tumor growth 















Figure 17: Effect of single dose treatment on tumorigenic activity of H69AR cells grown 
as 3D spheroids simulating in-vivo tumor conditions. (A) % Cell viability of spheroids 
obtained using Cell-titer glo™ 3D calculated relative to untreated cells (control) considered 
as 100%. Data represents mean±SD (n=3). (B) Representative florescent images of 
spheroids after staining the live cells with calcein AM dye at the end of day 6. 
****p<0.0001. 
 
The 3D spheroids model represent a solid mass of tumor cells growing 
exponentially in all the direction and therefore, optical imaging may not completely reflect 
treatment’s efficiency. Therefore, % cell viability in 3D spheroids was performed to 
determine % viable cells present in the tumor after the treatment period. Figure 17C 
represents the % cell viability of 3D spheroids for each treatment group, wherein DOX 
shows 24.2 ± 2.0 % viability in spheroids after 6 days. Treatment with 10µm-Sph, 
demonstrated 65.1 ± 4.4 % viability while the stretched particles demonstrated significantly 
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(p<0.0001) lower cell viability with 26.0 ± 2.1 % viability for 10µm-SR and 23.5 ± 3.1 % 
viability for 10µm-LR (Figure 17C). These results indicate that treatment with the 
stretched particles results into evident reduction in % viability compared to the spherical 
particles. This data is also in accordance with the optical imaging data and tumor spheroid 
volume establishing the particle shape effects against the 3D spheroids tumorigenic 
activity. 
To further validate the effectiveness of treatment groups against SCLC spheroids, 
live cells present in the spheroids were imaged after staining with calcein AM dye 
(providing green florescence). Figure 17D displays the florescent images of viable cells in 
3D spheroids present in each treatment group. As can be inferred from the figure, control 
has intense bright green florescence indicating the presence of live cells. Further, treatment 
with DOX resulted into inhibition of the tumor growth when compared to control with 
reduced viable cells being present in the spheroids. For 10µm-Sph, even though the size of 
the spheroids was not significantly reduced, the florescence of the viable cells was 
diminished (Figure 17D). This can be suggestive of the fact that 10µm-Sph may be able 
to show cytotoxic effects without impacting the tumor size and the integrity of the 
spheroids, however this effect was non-significant. On the contrary, treatment with rod-
shaped particles (10µm-SR and 10µm-LR) resulted into reduction in tumor size as well as 
diminished florescence of viable cells compared to spherical particles indicating their 
superior anti-tumorigenic activity (Figure 17D). These results are indicative of the fact 


















Figure 18: Effect of multiple dose treatment on tumorigenic activity of H69AR cells grown 
as 3D spheroids simulating in-vivo tumor conditions. (A) Representative images of 
spheroids demonstrating suppression in tumor growth at days 0, 3 and 6. Scale bar = 200 
µm (B) Quantitative representation of anti-tumor activity of treatment expressed as 
spheroid volume (mm3) versus time (days) for multiple dose treatment. Data represent 




B) In-vitro Tumor Simulation Studies- Multiple Dose 
Multiple dose treatment revealed interesting results establishing the anti-tumor activity of 
various treatment groups. As seen in Figure 18A, the control group demonstrated 6.8 folds 
significant increase (p<0.001) in the tumor growth with 41.1 ± 3.4 mm3 spheroid volume 
at day 6 when compared to the initial (day 0) tumor volume (Figure 18B). DOX treatment 
resulted into inhibition of tumor growth and a significant (p<0.0001) 6.2 folds reduction 
in spheroid volume (6.6 ± 2.2 mm3) as compared to control (Figure 18B). Additionally, 
DOX also resulted into distortion of tumor integrity at Day 6 which is a characteristic anti-
tumorigenic activity of chemotherapeutic agent (Figure 18A). Treatment with DOX-
conjugated particles demonstrated the influence of particle shape on the treatment 
effectiveness. 10µm-Sph demonstrated significant  (p<0.001) reduction of 1.5 folds in 
spheroid volume with 27.5 ± 3.7 mm3 when compared to control. This effect was found to 
be more pronounced with treatment of rod-shaped particles 10µm-SR particles 
demonstrated a significant (p<0.0001) 7.0 folds reduction in spheroid growth with a tumor 
volume of 5.9 ± 0.5 mm3 as against control and ~5.0 folds reduction when compared to 
spherical particles (Figure 18A and 18B). Treatment with 10µm-LR particles resulted into 
5.6 ± 1.1 mm3 spheroid volume as in Figure 18B demonstrating a significant (p<0.0001) 
5.0 folds reduction as against 10µm-Sph. In addition to reduction in tumor growth and 
spheroid volume, it was interesting to observe that the rod-shaped particles impacted the 
tumor integrity which was found to be absent in the spherical particles . These results may 
be suggestive of the fact that rod-shaped particles possess better anti-tumorigenic activity 









Figure 19: Effect of multiple dose treatment on tumorigenic activity of H69AR cells grown 
as 3D spheroids simulating in-vivo tumor conditions. (A) % Cell viability of spheroids 
obtained using Cell-titer Glo™ 3D calculated relative to untreated cells (control) 
considered as 100%. Data represents mean±SD (n=3).  (B) Representative florescent 
images of spheroids after staining the live cells with calcein AM dye at the end of day 6. 
*p<0.05 and ****p<0.0001. 
 
% Cell viability of 3D spheroids for each treatment group was analyzed using 
luminescence to further support the data of microscopic imaging. As seen in Figure 19A, 
DOX demonstrated 22.7 ± 1.7% cell viability after 6 days. Upon evaluating DOX-
conjugated particles, shape dependent effect was predominantly observed with spherical 
particles demonstrating the lowest % viability with 59.7 ± 2.5 % while rod-shaped particles 
resulted into significant (p<0.0001) 3 folds reduction in viability with ~20 % cell viability. 
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Furthermore, treatment with 10µm-SR and 10µm-LR particles also resulted into significant 
(p<0.05) reduction in % cell viability as compared to free DOX. These results are in 
accordance with the tumor imaging and spheroids volume data signifying the importance 
of particle shape in improving the efficacy of treatment. 
The viable cells in the 3D spheroids were stained with calcein AM dye, to 
understand the therapeutic behavior of treatment groups by imaging the viable cells and 
further validate the microscopic and luminescence data. As seen in the Figure 19B, control 
group displays bright green florescence indicating the presence of viable cells. Treatment 
with  DOX resulted into reduction in the tumor size and the viable cells florescence as 
compared to control. Particle shape dependent effect on tumorigenic activity of H69AR 
spheroids was analyzed using 10µm-Sph, 10µm-SR, and 10µm-LR particles. The spherical 
particles indicated minimal reduction in the tumor size amongst the conjugated DOX 
particles (Figure 19B). However, the florescence of viable cells in the 10µm-Sph treatment 
was found to be diminished indicating that the spherical particles does show cytotoxicity 
without impacting the tumor integrity. Treatment with both the rod-shaped particles 
demonstrated reduction in tumor size unlike the spherical particles. Additionally, the 
florescence of the viable cells in both the groups was found to be diminished compared to 
free DOX treated spheroids (Figure 19B). These findings indicate the pronounced 
effectiveness of the particles upon changing the shape from spherical to rod-shape, thereby 
imparting better therapeutic activity. 
The results of in-vitro tumor simulation studies establish the superior anti-
tumorigenic activity of rod-shaped particles against spheres which may be suggestive of 
better penetrability of rod-shaped particles in the 3D spheroids. However, increase in AR 
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of rod-shaped particles did not significantly influence the penetrability in the spheroids as 
can be seen for SR and LR which are in accordance with previously reported studies 
[115,116]. Studies performed by Chauhan et al., demonstrated 1.7 folds improvement in 
penetration of nanorods against spherical counterparts evaluated in orthotopic E0771 
mammary tumors. Similarly, Black et al., performed in-vivo studies to evaluate the efficacy 
of various particle shape of radiolabeled silver nanoparticles (rods, disks, spheres, and 
cube)in penetrating the solid tumor upon intravenous administration. It was reported that 
rods and cube shaped particles penetrated to the core of tumor while the disk- and sphere-
shaped particles were predominantly located at the rim of the tumor [117]. These studies 
have reported the internalization of nanosized particles which may be internalized via 
mechanisms such as diffusion, endocytosis, or pinocytosis while the particles used in our 
project are micron-sized which are extensively internalized via phagocytosis wherein again 
the influence of shape has been severely signified [60,118]. The results of in-vitro tumor 
simulation therefore establish the improved effectiveness of treatment by change of particle 
shape form sphere to rod-shape. 
4.9 Investigating Impact on Cardiotoxicity 
Therapeutic use of DOX has been limited owing to its adverse side effects amongst 
which deposition of cumulative dose causes cardiotoxicity [119]. Clinically induced DOX 
cardiotoxicity leads to development of cardiomyopathy subsequently causing apoptosis 
and necrosis of cardiomyocytes leading to progressive cardiac failure [120]. Several 
mechanisms have been identified for development of DOX induced cardiotoxicity such as 
reactive oxygen species production, apoptosis, DNA damage, lipid peroxidation and 
autophagy [69]. As particle shape has shown to influence the internalization of particles in 
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normal cells like macrophages, with minimal uptake of high AR particles, we hypothesized 
that conjugation of DOX to rod shaped particles may result into reduced cardiotoxic 
activity of DOX due to reduced uptake.  
4.9.1 Cytotoxic Assessment on Cardiomyoblasts 
The viability of H9c2 rat cardiomyoblasts cells was analyzed using MTT assay after 24 
hours of exposure to various treatment groups as shown in Figure 20A.  As seen from the 
figure, DOX displayed dose dependent toxicity against H9c2 cells and the IC50 value of 
DOX was found to be 37.1 ± 3.0 µM which is in accordance with the IC50 value reported 
in literature. Treatment with 10µm-Sph displayed 1.6 folds reduction (p<0.001)  in 
cytotoxicity as compared to free DOX with 61.1 ± 7.2 % cell viability observed at 40 µM 
concentration, the highest concentration tested. Both the rod-shaped particles, 10µm-SR 
and 10µm-LR also demonstrated a significant (p<0.0001) reduction in the cytotoxicity as 
compared to the free DOX (Figure 20A). The % cell viability after treatment with 10µm-
SR particles was found to be 78.0 ±9.3 % cell viability while 10µm-LR particles showed 
80.3 ± 6.1 % cell viability at 40 µM concentration. These results clearly show that DOX-
conjugated particles resulted into lower cytotoxic effects against H9c2 cells. Amongst the 
DOX-conjugated particles, change in the shape of particle to rod-shape further resulted into 
























Figure 20: Influence of cardiotoxicity of DOX and DOX-conjugated particles after 
treatment of H9c2 cardiomyoblasts. (A) Cytotoxic potential of treatment groups evaluated 
after 24 hrs. treatments and expressed as % cell viability (n=6 for 3 individual 
experiments). (B) Apoptosis effect of free DOX and DOX-conjugated particles evaluated 
using Realtime-Glo™ expressed as luminescence intensity (n=6) and  (C) Representative 
florescence images of H9c2 cardiomyoblasts stained by AO/EB staining. Data represents 
mean±SD. ** p<0.01 and *** p<0.001. 
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4.9.2 Lactate Dehydrogenase (LDH) Assay 
LDH is a cytosolic enzyme released upon damage to the cell membrane and is well 
known marker of cell death or cell damage. Cell injury to H9c2 cardiomyoblasts after 
treatment for 24 hours was evaluated by measuring the LDH release in the media using the 
Promega Luminescence kit. As seen in Figure 20B free DOX (1.25 µM) induces the 
highest increase in the luminescence signal amongst all the treatment groups suggesting 
significant (p<0.001) LDH leakage in cell culture supernatant following 24 hours 
incubation. Therefore, indicating that exposure to free DOX resulted in significant damage 
to cell membrane. However, treatment with DOX-conjugated 10µm-Sph particles 
displayed a significant (p<0.01) reduction in the LDH release from H9c2 cells. 
Furthermore, incubation of cardiomyoblasts with rod-shaped particles i.e., 10µm-SR and 
10µm-LR resulted into 2.0 folds significant (p<0.001) reduction in the LDH activity as 
compared to free DOX (Figure 20B). The LDH activity of the DOX-conjugated particles 
were almost like the control indicating the role of microparticles in reducing the 
cardiotoxicity of free DOX. This can be attributed to the conjugation of DOX to 
polystyrene particles via a stable amide linkage which prevents DOX to be readily 
available. The small increase in LDH activity observed for 10µm-Sph compared to 10µm-
SR and 10µm-LR particles may be because of preferential internalization of spherical 




4.9.3 Apoptosis Evaluation in H9c2 cells 
Several in-vitro and in-vivo studies have reported that DOX induces apoptosis in 
the cardiomyocytes, thereby indicating that apoptosis is major pathway leading to cardiac 
dysfunction and eventually cardiac failure in patients. Figure 20C demonstrates the effect 
of free DOX and DOX-conjugated particles on the apoptosis induced damage in H9c2 
cardiomyocytes using acridine orange (AO)/ethidium bromide (EB) staining. Ethidium 
bromide enters the cell with compromised cell membrane integrity and stains the cells with 
red or orange fluorescence indicating the induction of apoptosis eventually causing cell 
death. The results demonstrate that exposure of cells to free DOX resulted into reduced cell 
viability and staining of the cells with red color indicating the presence of non-viable cells 
[69]. Treatment with all the DOX-conjugated particles showed absence of red/orange-
stained cells indicating absence of cytotoxic effects on the H9c2 cardiomyocytes (Figure 
20C). These results are in corroboration with the cytotoxicity and LDH activity assay 






In this project we demonstrated the interplay between the particle size and particle 
shape on the aerodynamic properties using NGI. Our results showed that change in the 
particle shape from spherical to rod-shaped display improved aerodynamic behavior of 
particles and this effect was amplified amongst particles with large equivalent diameter. 
Subsequently, we have assessed the influence of particle shape on escape of phagocytic 
uptake by macrophages wherein rod-shape particles displayed reduced uptake compared 
to spherical particles and this effect being higher for elongated particles having higher AR 
value. The current study also provides evidence about particle shape influence on the 
effectiveness of treatment against SCLC cells. Results demonstrated superior cytotoxic 
activity of rod-shaped particles against spherical particles. Importantly, these results were 
further validated using in-vitro tumor simulation studies wherein the rod-shaped particles 
have pronounced effect in inhibiting the tumor growth and distorting the tumor integrity 
which would help translation to preclinical settings. Furthermore, we have evaluated the 
particle shape effect on cardiotoxicity of DOX using DOX-conjugated in cardiomyoblasts. 
Results confirmed that elongated rod-shaped particles illustrated diminished cardiotoxicity 
on cells when compared to their spherical counterparts. Therefore, our findings provide 
valuable insights about particle shape influence on designing inhalable delivery carriers for 
pulmonary administration to combat respiratory diseases.  
Since this proof-of-concept study was performed using polystyrene particles which 
are non-biodegradable, the translation to preclinical setting remains challenging. 
Therefore, future studies may involve developing biodegradable particles of various shapes 
and evaluate  their impact on pulmonary deposition behavior. Moreover, the existing rod-
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shaped particles can be conjugated with other small molecules or large molecules such as 
targeting proteins. This strategy can be further  translated to fabricate  other biodegradable 
rod-shaped particles with tunable surface modifications for providing desired therapeutic 
effects. The biodegradable particles can be conjugated with variety of therapeutics or can 
be passively loaded with drug molecules of interest. In-vivo studies can be performed in 
orthotopic lung tumor model to further validate the influence of particle shape on the 
aerosolization efficiency and the therapeutic activity, thereby designing optimized delivery 






[1] Definition of respiratory disease - NCI Dictionary of Cancer Terms - National 
Cancer Institute, (2011). https://www.cancer.gov/publications/dictionaries/cancer-
terms/def/respiratory-disease (accessed January 10, 2021). 
[2] The top 10 causes of death, (n.d.). https://www.who.int/news-room/fact-
sheets/detail/the-top-10-causes-of-death (accessed March 12, 2019). 
[3] D.A. Groneberg, C. Witt, U. Wagner, K.F. Chung, A. Fischer, Fundamentals of 
pulmonary drug delivery, Respiratory Medicine. 97 (2003) 382–387. 
https://doi.org/10.1053/rmed.2002.1457. 
[4] N.R. Labiris, M.B. Dolovich, Pulmonary drug delivery. Part I: Physiological factors 
affecting therapeutic effectiveness of aerosolized medications, Br J Clin Pharmacol. 
56 (2003) 588–599. https://doi.org/10.1046/j.1365-2125.2003.01892.x. 
[5] J.M. Borghardt, C. Kloft, A. Sharma, Inhaled Therapy in Respiratory Disease: The 
Complex Interplay of Pulmonary Kinetic Processes, Canadian Respiratory Journal. 
2018 (2018) e2732017. https://doi.org/10.1155/2018/2732017. 
[6] J.L. Rau, The inhalation of drugs: advantages and problems, Respir Care. 50 (2005) 
367–382. 
[7] A.M. Le Roux, D. Kotze, C.A. Wium, P.P. Van Jaarsveld, J.R. Joubert, Inhaled and 
oral salbutamol: how effective in the prophylaxis of asthma?, Respiration. 58 (1991) 
192–197. https://doi.org/10.1159/000195925. 
[8] A. Dyreborg, N. Krogh, V. Backer, S. Rzeppa, P. Hemmersbach, M. Hostrup, 
Pharmacokinetics of Oral and Inhaled Terbutaline after Exercise in Trained Men, 
Front Pharmacol. 7 (2016). https://doi.org/10.3389/fphar.2016.00150. 
72 
 
[9] J.G.Y. Chan, J. Wong, Q.T. Zhou, S.S.Y. Leung, H.-K. Chan, Advances in Device 
and Formulation Technologies for Pulmonary Drug Delivery, AAPS PharmSciTech. 
15 (2014) 882–897. https://doi.org/10.1208/s12249-014-0114-y. 
[10] M. Shirley, Amikacin Liposome Inhalation Suspension: A Review in 
Mycobacterium avium Complex Lung Disease, Drugs. 79 (2019) 555–562. 
https://doi.org/10.1007/s40265-019-01095-z. 
[11] D.A. Edwards, Large Porous Particles for Pulmonary Drug Delivery, Science. 276 
(1997) 1868–1872. https://doi.org/10.1126/science.276.5320.1868. 
[12] I.M. El-Sherbiny, N.M. El-Baz, M.H. Yacoub, Inhaled nano- and microparticles for 
drug delivery, Global Cardiology Science and Practice. 2015 (2015) 2. 
https://doi.org/10.5339/gcsp.2015.2. 
[13] A.Y. Watson, R.R. Bates, D. Kennedy, Biological Disposition of Airborne Particles: 
Basic Principles and Application to Vehicular Emissions, National Academies Press 
(US), 1988. https://www.ncbi.nlm.nih.gov/books/NBK218161/ (accessed 
September 12, 2020). 
[14] S.G. Klein, J. Hennen, T. Serchi, B. Blömeke, A.C. Gutleb, Potential of coculture in 
vitro models to study inflammatory and sensitizing effects of particles on the lung, 
Toxicology in Vitro. 25 (2011) 1516–1534. 
https://doi.org/10.1016/j.tiv.2011.09.006. 
[15] K.P. O’Donnell, H.D.C. Smyth, Macro- and Microstructure of the Airways for Drug 
Delivery, in: H.D.C. Smyth, A.J. Hickey (Eds.), Controlled Pulmonary Drug 




[16] M. Ochs, J.R. Nyengaard, A. Jung, L. Knudsen, M. Voigt, T. Wahlers, J. Richter, 
H.J.G. Gundersen, The Number of Alveoli in the Human Lung, Am J Respir Crit 
Care Med. 169 (2004) 120–124. https://doi.org/10.1164/rccm.200308-1107OC. 
[17] J.S. Patil, S. Sarasija, Pulmonary drug delivery strategies: A concise, systematic 
review, Lung India. 29 (2012) 44–49. https://doi.org/10.4103/0970-2113.92361. 
[18] S. Toppila-Salmi, J. Renkonen, S. Joenväärä, P. Mattila, R. Renkonen, Allergen 
interactions with epithelium, Current Opinion in Allergy and Clinical Immunology. 
11 (2011) 29–32. https://doi.org/10.1097/ACI.0b013e328342319e. 
[19] T.J. Franks, T.V. Colby, W.D. Travis, R.M. Tuder, H.Y. Reynolds, A.R. Brody, 
W.V. Cardoso, R.G. Crystal, C.J. Drake, J. Engelhardt, M. Frid, E. Herzog, R. 
Mason, S.H. Phan, S.H. Randell, M.C. Rose, T. Stevens, J. Serge, M.E. Sunday, J.A. 
Voynow, B.M. Weinstein, J. Whitsett, M.C. Williams, Resident Cellular 
Components of the Human Lung, Proc Am Thorac Soc. 5 (2008) 763–766. 
https://doi.org/10.1513/pats.200803-025HR. 
[20] M.M. Chang, L. Shih, R. Wu, 1 Pulmonary Epithelium: Cell Types and Functions, 
n.d. 
[21] B.S. Schuster, J.S. Suk, G.F. Woodworth, J. Hanes, Nanoparticle diffusion in 
respiratory mucus from humans without lung disease, Biomaterials. 34 (2013) 3439–
3446. https://doi.org/10.1016/j.biomaterials.2013.01.064. 
[22] D.T. Edizer, O. Yigit, M. Rudenko, Mucociliary Clearance and Its Importance, in: 
C. Cingi, N. Bayar Muluk (Eds.), All Around the Nose: Basic Science, Diseases and 




[23] J.V. Fahy, B.F. Dickey, Airway mucus function and dysfunction, N. Engl. J. Med. 
363 (2010) 2233–2247. https://doi.org/10.1056/NEJMra0910061. 
[24] F. Taherali, F. Varum, A.W. Basit, A slippery slope: On the origin, role and 
physiology of mucus, Advanced Drug Delivery Reviews. 124 (2018) 16–33. 
https://doi.org/10.1016/j.addr.2017.10.014. 
[25] J.A. Frank, Claudins and alveolar epithelial barrier function in the lung, Ann N Y 
Acad Sci. 1257 (2012) 175–183. https://doi.org/10.1111/j.1749-6632.2012.06533.x. 
[26] C.A. Ruge, J. Kirch, O. Cañadas, M. Schneider, J. Perez-Gil, U.F. Schaefer, C. 
Casals, C.-M. Lehr, Uptake of nanoparticles by alveolar macrophages is triggered 
by surfactant protein A, Nanomedicine. 7 (2011) 690–693. 
https://doi.org/10.1016/j.nano.2011.07.009. 
[27] T. Tschernig, N.T. Veith, E. Diler, M. Bischoff, C. Meier, M. Schicht, The 
importance of surfactant proteins—New aspects on macrophage phagocytosis, 
Annals of Anatomy - Anatomischer Anzeiger. 208 (2016) 142–145. 
https://doi.org/10.1016/j.aanat.2016.07.005. 
[28] R. Guagliardo, J. Pérez-Gil, S. De Smedt, K. Raemdonck, Pulmonary surfactant and 
drug delivery: Focusing on the role of surfactant proteins, Journal of Controlled 
Release. 291 (2018) 116–126. https://doi.org/10.1016/j.jconrel.2018.10.012. 
[29] S. Ariki, C. Nishitani, Y. Kuroki, Diverse Functions of Pulmonary Collectins in Host 




[30] J.A. Whitsett, T.E. Weaver, Hydrophobic Surfactant Proteins in Lung Function and 
Disease, New England Journal of Medicine. 347 (2002) 2141–2148. 
https://doi.org/10.1056/NEJMra022387. 
[31] K. BéruBé, Z. Prytherch, C. Job, T. Hughes, Human primary bronchial lung cell 
constructs: The new respiratory models, Toxicology. 278 (2010) 311–318. 
https://doi.org/10.1016/j.tox.2010.04.004. 
[32] C.A. Ruge, J. Kirch, C.-M. Lehr, Pulmonary drug delivery: from generating aerosols 
to overcoming biological barriers—therapeutic possibilities and technological 
challenges, The Lancet Respiratory Medicine. 1 (2013) 402–413. 
https://doi.org/10.1016/S2213-2600(13)70072-9. 
[33] J. Heyder, Deposition of Inhaled Particles in the Human Respiratory Tract and 
Consequences for Regional Targeting in Respiratory Drug Delivery, Proceedings of 
the American Thoracic Society. 1 (2004) 315–320. 
https://doi.org/10.1513/pats.200409-046TA. 
[34] M. Lippmann, D.B. Yeates, R.E. Albert, Deposition, retention, and clearance of 
inhaled particles., Br J Ind Med. 37 (1980) 337–362. 
[35] C. Darquenne, Aerosol Deposition in Health and Disease, J Aerosol Med Pulm Drug 
Deliv. 25 (2012) 140–147. https://doi.org/10.1089/jamp.2011.0916. 
[36] C. Darquenne, Deposition Mechanisms, Journal of Aerosol Medicine and 




[37] A. Tsuda, F.S. Henry, J.P. Butler, Particle Transport and Deposition: Basic Physics 
of Particle Kinetics, in: Comprehensive Physiology, American Cancer Society, 
2013: pp. 1437–1471. https://doi.org/10.1002/cphy.c100085. 
[38] Y.S. Cheng, Aerosol Deposition in the Extrathoracic Region, Aerosol Science and 
Technology. 37 (2003) 659–671. https://doi.org/10.1080/02786820300906. 
[39] T.S. Wiedmann, R. Bhatia, L.W. Wattenberg, Drug solubilization in lung surfactant, 
Journal of Controlled Release. 65 (2000) 43–47. https://doi.org/10.1016/S0168-
3659(99)00230-8. 
[40] G. Oberdörster, Lung Clearance of Inhaled Insoluble and Soluble Particles, Journal 
of Aerosol Medicine. 1 (1988) 289–330. https://doi.org/10.1089/jam.1988.1.289. 
[41] H. Nakane, Translocation of particles deposited in the respiratory system: a 
systematic review and statistical analysis, Environ Health Prev Med. 17 (2012) 263–
274. https://doi.org/10.1007/s12199-011-0252-8. 
[42] H.S. Choi, Y. Ashitate, J.H. Lee, S.H. Kim, A. Matsui, N. Insin, M.G. Bawendi, M. 
Semmler-Behnke, J.V. Frangioni, A. Tsuda, Rapid Translocation of Nanoparticles 
from the Lung Airspaces to the Body, Nat Biotechnol. 28 (2010) 1300–1303. 
https://doi.org/10.1038/nbt.1696. 
[43] Y. Liu, A. Ibricevic-Richardson, J.A. Cohen, J.L. Cohen, S.P. Gunsten, J.M.J. 
Fréchet, M.J. Walter, M.J. Welch, S.L. Brody, Impact of hydrogel nanoparticle size 
and functionalization on in vivo behavior for lung imaging and therapeutics, Mol 
Pharm. 6 (2009) 1891–1902. https://doi.org/10.1021/mp900215p. 
[44] A. Buckley, J. Warren, A. Hodgson, T. Marczylo, K. Ignatyev, C. Guo, R. Smith, 
Slow lung clearance and limited translocation of four sizes of inhaled iridium 
77 
 
nanoparticles, Particle and Fibre Toxicology. 14 (2017) 5. 
https://doi.org/10.1186/s12989-017-0185-5. 
[45] C.M. Evans, J.S. Koo, Airway mucus: the good, the bad, the sticky, Pharmacol. 
Ther. 121 (2009) 332–348. https://doi.org/10.1016/j.pharmthera.2008.11.001. 
[46] S. Schürch, P. Gehr, V. Im Hof, M. Geiser, F. Green, Surfactant displaces particles 
toward the epithelium in airways and alveoli, Respir Physiol. 80 (1990) 17–32. 
https://doi.org/10.1016/0034-5687(90)90003-h. 
[47] W. Stahlhofen, R. Koebrich, G. Rudolf, G. Scheuch, Short-term and long-term 
clearance of particles from the upper human respiratory tract as function of particle 
size, Journal of Aerosol Science. 21 (1990) S407–S410. 
https://doi.org/10.1016/0021-8502(90)90267-2. 
[48] G. Scheuch, W. Stahlhofen, Particle Deposition of Inhaled Aerosol Boluses in the 
Upper Human Airways, Journal of Aerosol Medicine. 1 (1988) 29–36. 
https://doi.org/10.1089/jam.1988.1.29. 
[49] J.R.H. Smith, M.R. Bailey, G. Etherington, A.L. Shutt, M.J. Youngman, Effect of 
Particle Size on Slow Particle Clearance from the Bronchial Tree, Experimental 
Lung Research. 34 (2008) 287–312. https://doi.org/10.1080/01902140802093196. 
[50] A. Henning, M. Schneider, N. Nafee, L. Muijs, E. Rytting, X. Wang, T. Kissel, D. 
Grafahrend, D. Klee, C.-M. Lehr, Influence of Particle Size and Material Properties 
on Mucociliary Clearance from the Airways, Journal of Aerosol Medicine and 




[51] J.C. Hogg, Response of the lung to inhaled particles, Medical Journal of Australia. 
142 (1985) 675–678. https://doi.org/10.5694/j.1326-5377.1985.tb113589.x. 
[52] M. Geiser, Update on Macrophage Clearance of Inhaled Micro- and Nanoparticles, 
Journal of Aerosol Medicine and Pulmonary Drug Delivery. 23 (2010) 207–217. 
https://doi.org/10.1089/jamp.2009.0797. 
[53] P.G. Holt, D.H. Strickland, M.E. Wikström, F.L. Jahnsen, Regulation of 
immunological homeostasis in the respiratory tract, Nature Reviews Immunology. 8 
(2008) 142–152. https://doi.org/10.1038/nri2236. 
[54] D.M. Ward, D.P. Hackenyos, J. Kaplan, Fusion of sequentially internalized vesicles 
in alveolar macrophages., J Cell Biol. 110 (1990) 1013–1022. 
https://doi.org/10.1083/jcb.110.4.1013. 
[55] B. Patel, N. Gupta, F. Ahsan, Particle engineering to enhance or lessen particle 
uptake by alveolar macrophages and to influence the therapeutic outcome, European 
Journal of Pharmaceutics and Biopharmaceutics. 89 (2015) 163–174. 
https://doi.org/10.1016/j.ejpb.2014.12.001. 
[56] J.V. Castell, M. Teresa Donato, M.J. Gómez-Lechón, Metabolism and bioactivation 
of toxicants in the lung. The in vitro cellular approach, Experimental and 
Toxicologic Pathology. 57 (2005) 189–204. 
https://doi.org/10.1016/j.etp.2005.05.008. 
[57] R. Upton, D. Doolette, Kinetic Aspects of Drug Disposition in the Lungs, Clinical 




[58] M. Gabriele, P. Puccini, M. Lucchi, A. Vizziello, P.G. Gervasi, V. Longo, Presence 
and inter-individual variability of carboxylesterases (CES1 and CES2) in human 
lung, Biochemical Pharmacology. 150 (2018) 64–71. 
https://doi.org/10.1016/j.bcp.2018.01.028. 
[59] S. Chakraborti, J. Sarkar, P.K. Pramanik, T. Chakraborti, Role of Proteases in Lung 
Disease: A Brief Overview, in: S. Chakraborti, T. Chakraborti, N.S. Dhalla (Eds.), 
Proteases in Human Diseases, Springer, Singapore, 2017: pp. 333–374. 
https://doi.org/10.1007/978-981-10-3162-5_16. 
[60] J.A. Champion, S. Mitragotri, Shape Induced Inhibition of Phagocytosis of Polymer 
Particles, Pharm Res. 26 (2009) 244–249. https://doi.org/10.1007/s11095-008-
9626-z. 
[61] J.A. Champion, S. Mitragotri, Role of target geometry in phagocytosis, PNAS. 103 
(2006) 4930–4934. https://doi.org/10.1073/pnas.0600997103. 
[62] R.S. Elbatanony, V. Parvathaneni, N.S. Kulkarni, S.K. Shukla, G. Chauhan, N.K. 
Kunda, V. Gupta, Afatinib-loaded inhalable PLGA nanoparticles for localized 
therapy of non-small cell lung cancer (NSCLC)—development and in-vitro efficacy, 
Drug Deliv. and Transl. Res. (2020). https://doi.org/10.1007/s13346-020-00802-8. 
[63] B. Vaidya, N.S. Kulkarni, S.K. Shukla, V. Parvathaneni, G. Chauhan, J.K. Damon, 
A. Sarode, J.V. Garcia, N. Kunda, S. Mitragotri, V. Gupta, Development of inhalable 
quinacrine loaded bovine serum albumin modified cationic nanoparticles: 
Repurposing quinacrine for lung cancer therapeutics, International Journal of 
Pharmaceutics. 577 (2020) 118995. https://doi.org/10.1016/j.ijpharm.2019.118995. 
80 
 
[64] S.K. Shukla, N.S. Kulkarni, P. Farrales, D.D. Kanabar, V. Parvathaneni, N.K. 
Kunda, A. Muth, V. Gupta, Sorafenib Loaded Inhalable Polymeric Nanocarriers 
against Non-Small Cell Lung Cancer, Pharm Res. 37 (2020) 67. 
https://doi.org/10.1007/s11095-020-02790-3. 
[65] M.E. Abdelrahim, H. Chrystyn, Aerodynamic Characteristics of Nebulized 
Terbutaline Sulphate Using the Next Generation Impactor (NGI) and CEN Method, 
Journal of Aerosol Medicine and Pulmonary Drug Delivery. 22 (2009) 19–28. 
https://doi.org/10.1089/jamp.2008.0650. 
[66] I. Takeuchi, Y. Taniguchi, Y. Tamura, K. Ochiai, K. Makino, Effects of l-leucine on 
PLGA microparticles for pulmonary administration prepared using spray drying: 
Fine particle fraction and phagocytotic ratio of alveolar macrophages, Colloids and 
Surfaces A: Physicochemical and Engineering Aspects. 537 (2018) 411–417. 
https://doi.org/10.1016/j.colsurfa.2017.10.047. 
[67] S.K. Shukla, A. Chan, V. Parvathaneni, V. Gupta, Metformin-loaded chitosomes for 
treatment of malignant pleural mesothelioma – A rare thoracic cancer, International 
Journal of Biological Macromolecules. 160 (2020) 128–141. 
https://doi.org/10.1016/j.ijbiomac.2020.05.146. 
[68] M.K. Kauffman, M.E. Kauffman, H. Zhu, Z. Jia, Y.R. Li, Fluorescence-Based 
Assays for Measuring doxorubicin in Biological Systems, React Oxyg Species 
(Apex). 2 (2016) 432–439. https://doi.org/10.20455/ros.2016.873. 
[69] S.M. Chacko, K.G. Nevin, R. Dhanyakrishnan, B.P. Kumar, Protective effect of p-
coumaric acid against doxorubicin induced toxicity in H9c2 cardiomyoblast cell 
81 
 
lines, Toxicol Rep. 2 (2015) 1213–1221. 
https://doi.org/10.1016/j.toxrep.2015.08.002. 
[70] Physical, Thermal, and Mechanical Properties of Polymers, in: Biosurfaces, John 
Wiley & Sons, Ltd, 2014: pp. 329–344. 
https://doi.org/10.1002/9781118950623.app1. 
[71] M. Cooley, A. Sarode, M. Hoore, D.A. Fedosov, S. Mitragotri, A. Sen Gupta, 
Influence of particle size and shape on their margination and wall-adhesion: 
implications in drug delivery vehicle design across nano-to-micro scale, Nanoscale. 
10 (2018) 15350–15364. https://doi.org/10.1039/C8NR04042G. 
[72] D. Missirlis, R. Kawamura, N. Tirelli, J.A. Hubbell, Doxorubicin encapsulation and 
diffusional release from stable, polymeric, hydrogel nanoparticles, European Journal 
of Pharmaceutical Sciences. 29 (2006) 120–129. 
https://doi.org/10.1016/j.ejps.2006.06.003. 
[73] B. Manocha, A. Margaritis, Controlled Release of Doxorubicin from Doxorubicin/-
Polyglutamic Acid Ionic Complex, Journal of Nanomaterials. 2010 (2010) e780171. 
https://doi.org/10.1155/2010/780171. 
[74] J. Ding, G. Xue, Q. Dai, R. Cheng, Glass transition temperature of polystyrene 
microparticles, Polymer. 34 (1993) 3325–3327. https://doi.org/10.1016/0032-
3861(93)90412-4. 
[75] J. Rieger, The glass transition temperature of polystyrene, Journal of Thermal 
Analysis. 46 (1996) 965–972. https://doi.org/10.1007/BF01983614. 
82 
 
[76] A. Vigevani, M.J. Williamson, Doxorubicin, in: Analytical Profiles of Drug 
Substances, Elsevier, 1981: pp. 245–274. https://doi.org/10.1016/S0099-
5428(08)60143-4. 
[77] G. Das, A. Nicastri, M.L. Coluccio, F. Gentile, P. Candeloro, G. Cojoc, C. Liberale, 
F. De Angelis, E. Di Fabrizio, FT-IR, Raman, RRS measurements and DFT 
calculation for Doxorubicin, Microsc. Res. Tech. (2010) NA-NA. 
https://doi.org/10.1002/jemt.20849. 
[78] Z.Q. Samra, S. Ahmad, M. Javeid, N. Dar, M.S. Aslam, I. Gull, M.M. Ahmad, 
ANTICANCER MEDICINES (DOXORUBICIN AND METHOTREXATE) 
CONJUGATED WITH MAGNETIC NANOPARTICLES FOR TARGETING 
DRUG DELIVERY THROUGH IRON, Preparative Biochemistry and 
Biotechnology. 43 (2013) 781–797. 
https://doi.org/10.1080/10826068.2013.782042. 
[79] V. Hermán, H. Takacs, F. Duclairoir, O. Renault, J.H. Tortai, B. Viala, Core double–
shell cobalt/graphene/polystyrene magnetic nanocomposites synthesized by in situ 
sonochemical polymerization, RSC Adv. 5 (2015) 51371–51381. 
https://doi.org/10.1039/C5RA06847A. 
[80] J. Fang, Y. Xuan, Q. Li, Preparation of polystyrene spheres in different particle sizes 
and assembly of the PS colloidal crystals, Science China-Technological Sciences - 
SCI CHINA-TECHNOL SCI. 53 (2010) 3088–3093. 
https://doi.org/10.1007/s11431-010-4110-5. 
[81] A.A.P. Mansur, S.M. Carvalho, Z.I.P. Lobato, M. de F. Leite, A. da S. Cunha, H.S. 
Mansur, Design and Development of Polysaccharide-Doxorubicin-Peptide 
83 
 
Bioconjugates for Dual Synergistic Effects of Integrin-Targeted and Cell-
Penetrating Peptides for Cancer Chemotherapy, Bioconjugate Chem. 29 (2018) 
1973–2000. https://doi.org/10.1021/acs.bioconjchem.8b00208. 
[82] J.S. Shankaranarayanan, J.R. Kanwar, A.J.A. AL-Juhaishi, R.K. Kanwar, 
Doxorubicin Conjugated to Immunomodulatory Anticancer Lactoferrin Displays 
Improved Cytotoxicity Overcoming Prostate Cancer Chemo resistance and Inhibits 
Tumour Development in TRAMP Mice, Scientific Reports. 6 (2016) 32062. 
https://doi.org/10.1038/srep32062. 
[83] R. Sturm, A Computer Model for the Simulation of Nonspherical Particle Dynamics 
in the Human Respiratory Tract, Physics Research International. 2012 (2012) 
e142756. https://doi.org/10.1155/2012/142756. 
[84] M. Shams, G. Ahmadi, H. Rahimzadeh, Transport and deposition of flexible fibers 
in turbulent duct flows, Journal of Aerosol Science. 32 (2001) 525–547. 
https://doi.org/10.1016/S0021-8502(00)00099-9. 
[85] R. Sturm, W. Hofmann, A computer program for the simulation of fiber deposition 
in the human respiratory tract, Computers in Biology and Medicine. 36 (2006) 1252–
1267. https://doi.org/10.1016/j.compbiomed.2005.07.004. 
[86] T.B. Martonen, I.M. Katz, Deposition Patterns of Aerosolized Drugs Within Human 
Lungs: Effects of Ventilatory Parameters, Pharm Res. 10 (1993) 871–878. 
https://doi.org/10.1023/A:1018913311788. 
[87] C. Darquenne, Aerosol Deposition in Health and Disease, J Aerosol Med Pulm Drug 
Deliv. 25 (2012) 140–147. https://doi.org/10.1089/jamp.2011.0916. 
84 
 
[88] J. Wang, J. Bhattacharyya, E. Mastria, A. Chilkoti, A quantitative study of the 
intracellular fate of pH-responsive Doxorubicin-polypeptide nanoparticles, J 
Control Release. 260 (2017) 100–110. 
https://doi.org/10.1016/j.jconrel.2017.05.032. 
[89] M. Li, Z. Tang, J. Lin, Y. Zhang, S. Lv, W. Song, Y. Huang, X. Chen, Synergistic 
antitumor effects of Doxorubicin-loaded carboxymethyl cellulose nanoparticle in 
combination with endostar for effective treatment of non-small-cell lung cancer, 
Adv Healthc Mater. 3 (2014) 1877–1888. https://doi.org/10.1002/adhm.201400108. 
[90] L. He, H. Liang, L. Lin, B.R. Shah, Y. Li, Y. Chen, B. Li, Green-step assembly of 
low density lipoprotein/sodium carboxymethyl cellulose nanogels for facile loading 
and pH-dependent release of Doxorubicin, Colloids and Surfaces B: Biointerfaces. 
126 (2015) 288–296. https://doi.org/10.1016/j.colsurfb.2014.12.024. 
[91] T. Etrych, V. Subr, R. Laga, B. Ríhová, K. Ulbrich, Polymer conjugates of 
Doxorubicin bound through an amide and hydrazone bond: Impact of the carrier 
structure onto synergistic action in the treatment of solid tumours, Eur J Pharm Sci. 
58 (2014) 1–12. https://doi.org/10.1016/j.ejps.2014.02.016. 
[92] Q. Gao, X. Han, J. Zhu, R. Chen, B. Sun, A polymer–drug conjugate for 
Doxorubicin: Synthesis and biological evaluation of pluronic F127-DOXorubicin 
amide conjugates, Journal of Applied Polymer Science. 124 (2012) 4953–4960. 
https://doi.org/10.1002/app.35613. 
[93] Y. Yu, C.-K. Chen, W.-C. Law, H. Sun, P.N. Prasad, C. Cheng, A degradable brush 
polymer–drug conjugate for pH-responsive release of Doxorubicin, Polym. Chem. 
6 (2015) 953–961. https://doi.org/10.1039/C4PY01194E. 
85 
 
[94] S. Mahesh, K.-C. Tang, M. Raj, Amide Bond Activation of Biological Molecules, 
Molecules. 23 (2018). https://doi.org/10.3390/molecules23102615. 
[95] M. Munerati, R. Cortesi, D. Ferrari, F. Di Virgilio, C. Nastruzzi, Macrophages 
loaded with Doxorubicin by ATP-mediated permeabilization: potential carriers for 
antitumor therapy, Biochim Biophys Acta. 1224 (1994) 269–276. 
https://doi.org/10.1016/0167-4889(94)90200-3. 
[96] L. Wang, Y. Song, A. Parikh, P. Joyce, R. Chung, L. Liu, F. Afinjuomo, J.D. 
Hayball, N. Petrovsky, T.G. Barclay, S. Garg, DOXorubicin-Loaded Delta Inulin 
Conjugates for Controlled and Targeted Drug Delivery: Development, 
Characterization, and In Vitro Evaluation, Pharmaceutics. 11 (2019) 581. 
https://doi.org/10.3390/pharmaceutics11110581. 
[97] M.P. Mohning, S.M. Thomas, L. Barthel, K.J. Mould, A.L. McCubbrey, S.C. 
Frasch, D.L. Bratton, P.M. Henson, W.J. Janssen, Phagocytosis of microparticles by 
alveolar macrophages during acute lung injury requires MerTK, American Journal 
of Physiology-Lung Cellular and Molecular Physiology. 314 (2017) L69–L82. 
https://doi.org/10.1152/ajplung.00058.2017. 
[98] J.A. Champion, S. Mitragotri, Shape Induced Inhibition of Phagocytosis of Polymer 
Particles, Pharm Res. 26 (2009) 244–249. https://doi.org/10.1007/s11095-008-
9626-z. 
[99] N. Doshi, S. Mitragotri, Macrophages Recognize Size and Shape of Their Targets, 
PLoS One. 5 (2010). https://doi.org/10.1371/journal.pone.0010051. 
[100] N. Chatterjee, J. Yang, S. Kim, S.W. Joo, J. Choi, Diameter size and aspect ratio as 
critical determinants of uptake, stress response, global metabolomics and epigenetic 
86 
 
alterations in multi-wall carbon nanotubes, Carbon. 108 (2016) 529–540. 
https://doi.org/10.1016/j.carbon.2016.07.031. 
[101] R.L. Siegel, K.D. Miller, A. Jemal, Cancer statistics, 2020, CA A Cancer J Clin. 70 
(2020) 7–30. https://doi.org/10.3322/caac.21590. 
[102] S. Haddadin, M.C. Perry, History of Small-Cell Lung Cancer, Clinical Lung Cancer. 
12 (2011) 87–93. https://doi.org/10.1016/j.cllc.2011.03.002. 
[103] J.D. Whitt, A.B. Keeton, B.D. Gary, L.A. Sklar, K. Sodani, Z.-S. Chen, G.A. Piazza, 
Sulindac sulfide selectively increases sensitivity of ABCC1 expressing tumor cells 
to doxorubicin and glutathione depletion, J Biomed Res. 30 (2016) 120–133. 
https://doi.org/10.7555/JBR.30.20150108. 
[104] A. Sampson, B.G. Peterson, K.W. Tan, S.H. Iram, Doxorubicin as a fluorescent 
reporter identifies novel MRP1 (ABCC1) inhibitors missed by calcein-based high 
content screening of anticancer agents, Biomedicine & Pharmacotherapy. 118 
(2019) 109289. https://doi.org/10.1016/j.biopha.2019.109289. 
[105] Y. He, K. Park, Effects of the Microparticle Shape on Cellular Uptake, Mol. 
Pharmaceutics. 13 (2016) 2164–2171. 
https://doi.org/10.1021/acs.molpharmaceut.5b00992. 
[106] S.E.A. Gratton, P.A. Ropp, P.D. Pohlhaus, J.C. Luft, V.J. Madden, M.E. Napier, 
J.M. DeSimone, The effect of particle design on cellular internalization pathways, 
PNAS. 105 (2008) 11613–11618. https://doi.org/10.1073/pnas.0801763105. 
[107] S. Wu, X. Yang, Y. Li, H. Wu, Y. Huang, L. Xie, Y. Zhang, Z. Hou, X. Liu, 
Preparation of HCPT-Loaded Nanoneedles with Pointed Ends for Highly Efficient 
87 
 
Cancer Chemotherapy, Nanoscale Res Lett. 11 (2016). 
https://doi.org/10.1186/s11671-016-1491-9. 
[108] N. Koundouros, G. Poulogiannis, Reprogramming of fatty acid metabolism in 
cancer, British Journal of Cancer. 122 (2020) 4–22. https://doi.org/10.1038/s41416-
019-0650-z. 
[109] M. Sok, M. Šentjurc, M. Schara, Membrane fluidity characteristics of human lung 
cancer, Cancer Letters. 139 (1999) 215–220. https://doi.org/10.1016/S0304-
3835(99)00044-0. 
[110] E.C. Costa, A.F. Moreira, D. de Melo-Diogo, V.M. Gaspar, M.P. Carvalho, I.J. 
Correia, 3D tumor spheroids: an overview on the tools and techniques used for their 
analysis, Biotechnology Advances. 34 (2016) 1427–1441. 
https://doi.org/10.1016/j.biotechadv.2016.11.002. 
[111] G. Mehta, A.Y. Hsiao, M. Ingram, G.D. Luker, S. Takayama, Opportunities and 
challenges for use of tumor spheroids as models to test drug delivery and efficacy, 
Journal of Controlled Release. 164 (2012) 192–204. 
https://doi.org/10.1016/j.jconrel.2012.04.045. 
[112] A.S. Nunes, A.S. Barros, E.C. Costa, A.F. Moreira, I.J. Correia, 3D tumor spheroids 
as in vitro models to mimic in vivo human solid tumors resistance to therapeutic 
drugs, Biotechnology and Bioengineering. 116 (2019) 206–226. 
https://doi.org/10.1002/bit.26845. 
[113] P. Benien, A. Swami, 3D tumor models: history, advances and future perspectives, 
Future Oncol. 10 (2014) 1311–1327. https://doi.org/10.2217/fon.13.274. 
88 
 
[114] Y. Imamura, T. Mukohara, Y. Shimono, Y. Funakoshi, N. Chayahara, M. Toyoda, 
N. Kiyota, S. Takao, S. Kono, T. Nakatsura, H. Minami, Comparison of 2D- and 
3D-culture models as drug-testing platforms in breast cancer, Oncol. Rep. 33 (2015) 
1837–1843. https://doi.org/10.3892/or.2015.3767. 
[115] R. Agarwal, P. Jurney, M. Raythatha, V. Singh, Sidlgata.V. Sreenivasan, L. Shi, K. 
Roy, Effect of Shape, Size, and Aspect Ratio on Nanoparticle Penetration and 
Distribution inside Solid Tissues Using 3D Spheroid Models, Adv. Healthcare 
Mater. 4 (2015) 2269–2280. https://doi.org/10.1002/adhm.201500441. 
[116] Y.-R. Zhang, R. Lin, H.-J. Li, W. He, J.-Z. Du, J. Wang, Strategies to improve tumor 
penetration of nanomedicines through nanoparticle design, WIREs Nanomed 
Nanobiotechnol. 11 (2019) e1519. https://doi.org/10.1002/wnan.1519. 
[117] K.C.L. Black, Y. Wang, H.P. Luehmann, X. Cai, W. Xing, B. Pang, Y. Zhao, C.S. 
Cutler, L.V. Wang, Y. Liu, Y. Xia, Radioactive 198Au-doped nanostructures with 
different shapes for in vivo analyses of their biodistribution, tumor uptake, and 
intratumoral distribution, ACS Nano. 8 (2014) 4385–4394. 
https://doi.org/10.1021/nn406258m. 
[118] A. Garapaty, J.A. Champion, Tunable particles alter macrophage uptake based on 
combinatorial effects of physical properties, Bioeng Transl Med. 2 (2017) 92–101. 
https://doi.org/10.1002/btm2.10047. 
[119] W.-B. Chung, H.-J. Youn, Pathophysiology and preventive strategies of 




[120] M. Dallons, C. Schepkens, A. Dupuis, V. Tagliatti, J.-M. Colet, New Insights About 
doxorubicin-Induced Toxicity to Cardiomyoblast-Derived H9C2 Cells and 
Dexrazoxane Cytoprotective Effect: Contribution of In Vitro 1H-NMR 






Name Snehal Shukla 
Baccalaureate Degree 
   
 
Bachelor of Pharmacy, Institute 
of Pharmacy, Nirma University, 
Ahmedabad 
 
Date Graduated May,2012 
Other Degrees and Certificates Master of Pharmacy, National 
Institute of Pharmaceutical 
Education and Research , 
Ahmedabad,                      
Major: Pharmaceutical 
Analysis 
 
Date Graduated 
 
 
 
June,2014 
 
 
 
